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A B S T R A C T
Background
Bronchiectasis is a chronic respiratory disease characterised by abnormal dilatation of the bronchi, and presents typically with a chronic
productive cough (or chronic wet cough in children) and recurrent infective exacerbations. It significantly impacts daily activities and
quality of life, and can lead to recurrent hospitalisations, severe lung function impairment, respiratory failure and even death.
Objectives
To provide an overview of the efficacy and safety of interventions for adults and children with bronchiectasis from Cochrane reviews.
To identify gaps in the evidence base that will inform recommendations for new research and reviews, and to summarise information
on reported outcomes and make recommendations for the reporting of standard outcomes in future trials and reviews.
Methods
We included Cochrane reviews of non-cystic fibrosis (CF) bronchiectasis. We searched the Cochrane Database of Systematic Reviews.
The search is current to 11 February 2015. We also identified trials that were potentially eligible for, but not currently included in,
published reviews tomake recommendations for new Cochrane reviews. We assessed the quality of included reviews using the AMSTAR
criteria. We presented an evidence synthesis of data from reviews alongside an evidence map of clinical trials and guideline data. The
primary outcomes were exacerbations, lung function and quality of life.
Main results
We included 21 reviews but extracted data from, and rated the quality of, only nine reviews that reported results for people with
bronchiectasis alone. Of the reviews with no usable data, two reviews included studies with mixed clinical populations where data were
not reported separately for people with bronchiectasis and 10 reviews did not contain any trials. Of the 40 studies included across the
nine reviews, three (number of participants nine to 34) included children. The studies ranged from single session to year-long studies.
Each review included from one to 11 trials and 28 (70%) trials in the overview included 40 or fewer participants. The total number
of participants included in reviews ranged from 40 to 1040. The age range of adult participants was from 36 to 73 years and children
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ranged from six to 16 years. The proportion of male participants ranged from 21% to 72%. Where reported, mean baseline forced
expiratory volume in one second (FEV1) ranged from 1.17 L to 1.66 L and from 47% to 88% predicted. Most of the reviews had
search dates older than two years.
We have summarised the published evidence as outlined in Cochrane reviews, but it was not possible to draw definitive conclusions.
There was inconclusive evidence on the use of long-term antibiotics and nebulised hypertonic saline for reducing exacerbation frequency
and evidence that human deoxyribonuclease (RhDNase) increases exacerbation frequency. Improvements in lung functionwere reported
for inhaled corticosteroids (ICS) though this was small and not clinically relevant. Evidence of benefit for hyperosmolar agents and
mucolytics was inconclusive. There was limited evidence of improvements in quality of life with airway clearance techniques and
physical therapy but evidence of benefit for hyperosmolar agents was inconclusive. Secondary outcomes were not clearly reported in
all trials in the included reviews. Improvements in dyspnoea, wheeze and cough-free days were reported for small trials of ICS and
LABA (long-acting beta2-agonsts)/ICS and cough reduction was also reported for a small bromhexine trial. Reduction in sputum
production was reported for long-term antibiotics and airway clearance techniques but evidence of benefit for hyperosmolar agents was
inconclusive.
Adverse events were included as outcomes in seven reviews. The review of long-term (four weeks to one year) prophylactic courses
of antibiotics reported significantly more cases of wheeze (Peto odd ratio (OR) 8.56, 95% confidence intervals (CI) 1.63 to 44.93),
dyspnoea (12 versus three, P value = 0.01) and chest pain (seven versus zero, P value = 0.01) from the same trial (74 participants) but no
differences in occurrence of diarrhoea, rash or number of withdrawals. In the review of mucolytics versus placebo, relevant outcomes
were not reported for erdosteine comparisons and no significant adverse effects were reported for bromhexine, though adverse events
were associated with RhDNase (OR 28.19, 95% CI 3.77 to 210.85, 1 study). Of the remaining five reviews, adverse events were not
reported in the single trials included in the ICS review or the physical therapy review and the impact of adverse events in the single
trial included in the inhaled LABA/ICS combination versus ICS review were unclear. The reviews of short-term courses of antibiotics
and inhaled hyperosmolar agents reported no significant differences in occurrence of adverse events. Fewer admissions to hospital were
reported for long-term antibiotics, but this outcome was not reported in all reviews. No reviews reported differences in mortality, but
again this outcome was not included in all reviews.
We did not explicitly include antibiotic resistance as an outcome in the review, but this was unclear in the Cochrane reviews and
evidence from other trials should be considered.
We rated all reviews as high quality (AMSTAR), though opportunities for improved reporting (e.g. summary of findings and GRADE
evaluation of the evidence) were identified for inclusion in future updates of the reviews. However, the majority of trials were not
high quality and confidence in the effects of treatments, therefore, requires additional evidence from larger and more methodologically
robust trials. We evaluated the overall coverage of important topics in bronchiectasis by mapping the quality of the current evidence
base against published guidelines and identifying high priority areas for new research on; use of short-course and long-term antibiotics,
ICS and oral corticosteroids, inhaled hyperosmolars, mucolytics, and use of airway clearance techniques.
Authors’ conclusions
This overview clearly points to significant opportunities for further research aimed at improving outcomes for people with bronchiectasis.
We have highlighted important endpoints for studies (particularly exacerbations, quality of life and lung function), and areas of clinical
practice that are in most urgent need of evidence-based support (including long-term antibiotics, ICSs and mucolytics).
As the evidence is confined to small trials of short duration, it is not currently possible to assess the balance between the benefits and
potential harms of treatments for bronchiectasis.
P L A I N L A N G U A G E S U M M A R Y
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
What is bronchiectasis?
Bronchiectasis is a long-term respiratory disease that is commonly associated with a troublesome cough productive of mucous (or
chronic wet cough in children) and recurrent flare-ups (exacerbations) due to lung infections. It significantly impacts upon normal
daily activities and quality of life, and can lead to recurrent hospitalisations, loss of lung function and even death.
2Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We looked at the available Cochrane reviews on bronchiectasis and found overall that there are relatively few trials and Cochrane reviews
available so it is difficult to draw helpful conclusions about how to treat bronchiectasis.
Overviews are designed to present the contents from a selection of reviews in a concise and helpful manner. To do this, we made an
evidence map of the available information from guidelines, clinical trials and Cochrane reviews, and highlighted the need for new
research. We have listed the most important outcomes for measuring benefit and harm in bronchiectasis (particularly exacerbations,
quality of life and lung function), and areas of clinical practice that are in most urgent need of evidence-based support (including long
term antibiotics, inhaled corticosteroids and mucolytics) in future studies.
The key findings for difference medicines and treatments were:
- Long-term antibiotics may reduce sputum (a mixture of saliva and mucous that is coughed up from the airways) production,
frequency of exacerbations and hospitalisation, but may also be associated with more frequent side effects (wheeze, dyspnoea (difficulty
in breathing) and chest pain).
- Inhaled corticosteroid treatment may improve lung function but the effect is small.
- Bromhexine may reduce cough, but evidence of benefit for hyperosmolar agents and mucolytics is generally unclear.
- Airway clearance techniques may reduce sputum production and improve quality of life.
- RhDNase (a medicine used to treat bronchiectasis) is associated with more frequent exacerbations.
- long-acting beta2-agonists/ICS combination therapy may reduce dyspnoea, wheeze and cough.
About 70% of trials in the reviews included in the overview were small (40 participants or fewer), which limits interpretation.
Side effects were reported in seven reviews:
- Long-term courses of antibiotics were associated with more cases of wheeze, breathlessness and chest pain, but we could not assess the
risks of developing antibiotic resistance.
- In the review comparing mucolytics (medicines that make the mucous less thick and sticky and easier to cough up) with placebo (a
pretend medicine), side effects were not reported for erdosteine comparisons. No significant side effects were reported for bromhexine,
though side effects were associated with RhDNase.
- Side effects were not reported in the single trials included in the inhaled corticosteroid review or the physical therapy review and the
impact of adverse events in the single trial included in the inhaled corticosteroid/long-acting beta2-agonists combination versus inhaled
corticosteroids review were unclear.
- The reviews of short-term courses of antibiotics and inhaled hyperosmolar agents reported no significant differences in occurrence of
side effects. Fewer admissions to hospital were reported for long-term antibiotics.
- No reviews reported significant differences in deaths between treatment and control groups, but only a small number of reviews
recorded deaths.
The included evidence came from:
- 21 Cochrane reviews, but there was only useable data in nine reviews.
- Forty trials were included in the nine reviews and 28 (70%) of the trials included 40 or fewer participants. Only three trials (nine to
34 participants) included children.
- Each review included from one to 11 trials.
- The studies ranged from single session to year-long studies.
- The total number of participants included in reviews ranged from 40 to 1040.
- The age range of adult participants was from 36 to 73 years and children ranged from six to 16 years.
- The included reviews were judged to be of high quality.
- However, the majority of trials in the bronchiectasis reviews were small and at risk of bias, so confidence in the effects of treatments
therefore requires additional evidence from larger and more methodologically robust trials
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B A C K G R O U N D
Description of the condition
Bronchiectasis is a condition defined by abnormal dilation of the
airways. This is typically associated with progressive airway de-
struction, due to the ’vicious cycle’ of recurrent bacterial infection,
inflammatory mediator release, airway damage and consequent
further infection (Cole 1997; Figure 1). In severe cases, this may
lead to repeated hospitalisation, chronic respiratory failure and
death.
Figure 1. The vicious cycle of bronchiectasis (Cole 1986).Treatment of both chronic disease and
exacerbations aims to intervene in this cycle. For example, long-term treatment with mucolytics and chest
clearance may be considered in an attempt to improve lung clearance, and thus remove the reservoir for
infection; vaccination or immunoglobulin replacement (in people who are deficient) targets impaired lung
defences; and prompt treatment with antibiotics, bronchodilators and chest clearance in exacerbations aims
to accelerate resolution and limit further airway damage.
4Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The diagnosis of bronchiectasis is made on clinico-radiographic
grounds, requiring identification of one or more abnormally di-
lated bronchi using high-resolution computerised tomography
(HRCT) scanning, together with appropriate symptoms (Chang
2010; Pasteur 2010). These symptoms may incorporate a chronic
and usually productive or wet cough together with recurrent lower
respiratory tract infections. People with bronchiectasis may also
experience breathlessness, wheeze, or both, and non-specific symp-
toms related to inflammatory burden, such as chest pains and
lethargy. Risk factors for accelerated decline in lung function may
include colonisation with Pseudomonas aeruginosa, and frequent
exacerbations (Evans 1996; Martinez-Garcia 2007). Colonisation
with P aeruginosa, impaired exercise capacity, wheeze, breathless-
ness and frequent exacerbations are all associated with a reduction
in quality of life (QoL) (Wilson 1997a; Wilson 1997b).
There is no consensus-based definition of bronchiectasis sever-
ity but a number of factors are associated with an increased risk
of hospitalisation and mortality including: low Forced expiratory
volume in one second) FEV1) % predicted, P aeruginosa colonisa-
tion, higher proportion of affected lobes, higherMedical Research
Council (MRC) dyspnoea score and more frequent annual exacer-
bation rate (Chalmers 2014;Martinez-Garcia 2014). Co-morbidi-
ties were not found to predict either mortality or hospitalisation
(Chalmers 2014). The Bronchiectasis Severity Index (Chalmers
2014) or FACED (Martinez-Garcia 2014) may identify high-risk
groups, but are unlikely to be used as outcomemeasures, as a num-
ber of component factors (e.g. lung function) are irreversible and,
therefore, not modifiable. The main aim of therapeutic manage-
ment is preservation of lung function, reduction of symptoms and
exacerbations, and improvement in QoL (Saleh 2014).
A cause for bronchiectasis should always be sought in the diagnos-
tic work-up. Although themajority of cases are either idiopathic or
due to a previous severe lung infection, treatable causes are found
in a significant minority of cases, such as immune-deficiency, aller-
gic bronchopulmonary aspergillosis, mycobacterial infection and
recurrent aspiration (Goeminne 2012; Pasteur 2000).
Prevalence of bronchiectasis
The true prevalence of bronchiectasis is unknown, with reported
figures confounded by variable aetiology and diagnostic strate-
gies (Weycker 2005), higher prevalence in developing countries
(Habesoglu 2011), and variability in reported prevalence metrics.
In one French series, 2.6% of respiratory outpatients had a con-
firmed diagnosis (Goeminne 2012). Evidence suggests an increase
in the global burden of bronchiectasis, with mortality rate in-
creasing at 3% per year between 2001 to 2007 in England and
Wales (Roberts 2010), and hospitalisations increasing by the same
percentage over a nine-year period in the US (Seitz 2010). Both
studies reported the steepest increase in prevalence rates in peo-
ple aged 60 years and over, and one further study by Seitz and
colleagues reported an increase of 8.7% per year in people over
65 year old in the US, with steeper increases in women compared
with men (Seitz 2012). Bronchiectasis prevalence rates may also
vary by ethnicity (Chang 2003; Seitz 2012). Prevalence rates are
potentially conservative due to under-diagnosis of bronchiectasis
(Roberts 2010), and the recent upwards trendsmay be attributable
in part to increasing awareness of the disease and more frequent
use of HRCT scanning (Seitz 2012).
Description of the interventions
Bronchiectasis is driven by a vicious cycle of breached defences,
infection, inflammation and tissue damage (Figure 1). Interven-
tions are indicated both for long-termmanagement and treatment
of exacerbations. In each case these can be divided into pharma-
cological and non-pharmacological interventions.
How the intervention might work
The principals of treatment for bronchiectasis are to improveQoL
as well as day-to-day symptoms (especially cough and breathless-
ness), to minimise the frequency and severity of exacerbations or
to reduce microbial load. Further aims of therapy, although more
difficult to demonstrate in short- or medium-term randomised
controlled trials (RCT), are to slow the decline in lung function
and reduce mortality.
Long-term management of bronchiectasis
Pharmacological interventions
Mucolytics are available in oral (e.g. carbocysteine, erdosteine) and
inhaled (e.g. mannitol, hypertonic saline) formulations and work
by reducing sputum viscosity, which eases expectoration, poten-
tially leading to reduced symptoms and exacerbation frequency
(Wilkinson 2014). Recombinant human DNase I (RhDNase) has
been used for the treatment of cystic fibrosis (CF) bronchiectasis,
with the aim of reducing the incidence of respiratory tract infec-
tion and improving lung function. However one trial of RhDNase
in adults with bronchiectasis was reported to show the treatment
to be ’ineffective and potentially harmful’ (O’Donnell 1998).
Inhaled bronchodilators act by relaxing smooth muscle, either
by activating the beta2-adrenoreceptor (salbutamol, terbutaline)
or blocking cholinergic transmission (ipratropium, tiotropium)
(Franco 2003; Sheikh 2001). Therefore, they are most effective in
people with bronchial smooth muscle hypertrophy, hyper-reactiv-
ity, or both. Theoretically bronchodilators may also improve mu-
cous clearance (Restrepo 2007). Conversely in people with severe
bronchial wall damage, bronchodilators may worsen symptoms if
the reduction in smooth muscle tone leads to further loss of struc-
tural integrity.
Anti-inflammatory medications in bronchiectasis include several
drug classes(e.g. corticosteroids, leukotriene receptor antagonists,
theophyllines and macrolides (given for their anti-inflammatory
rather than antibiotic effect)) (Corless 2000; Crosbie 2009; Kapur
2007; Steele 2000). The mechanism of action differs by drug class
5Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and theremay be different effects in people with specific subgroups
of disease.
Long-term antibiotics may be used where bacteria colonise the
airways, on the assumption that these bacteria cause persistent
symptoms and exacerbations (Evans 2003; Evans 2007). Antibi-
otics may be given either in nebulised or oral form.
Vaccination with both influenza and pneumococcal (pneumonia)
vaccines is recommended in British Thoracic Society (BTS) guide-
lines (Pasteur 2010).
Non-pharmacological interventions
Respiratory physiotherapy techniques “include mobilising and
aiding expectoration of bronchopulmonary secretions, improving
efficiency of ventilation, maintaining or improving exercise tol-
erance, improving knowledge and understanding, and reducing
breathlessness and (thoracic) pain” (Pasteur 2010). Chest clearance
methods, which can be assisted with positive expiratory pressure
devices, aim to improve chest clearance to reduce sputum (and
bacterial) load, improve day-to-day symptoms and reduce exacer-
bation frequency (Clarke 1989).
Where disease is isolated to a single anatomical area of the lung and
there is not an underlying and ongoing driver for bronchiectasis
that may predict recurrence, surgical removal of a section of the
lung may be indicated (Warburton 2000).
Pulmonary rehabilitation and exercise may help by improving res-
piratory fitness.
Long-term oxygen therapy and the treatment of secondary pul-
monary hypertension are other treatment options. However, de-
tailed discussion of these is beyond the scope of this review and
readers are directed to consensus statements, guidelines and gov-
ernment resources (Chang 2010; Hill 2011; NHLBI; Pasteur
2010).
Interventions for exacerbations of bronchiectasis
Pharmacological interventions
Mucolytics may be used in exacerbations, with the aim of improv-
ing sputum clearance and shortening recovery time. Bronchodila-
tors (often nebulised) are used with the aim of easing breathless-
ness, decreasing wheeze and promoting sputum clearance.
Anti-inflammatory treatments used in exacerbations may include
oral corticosteroids, typically where there is an asthmatic element
to the disease such as in allergic bronchopulmonary aspergillosis.
Theophyllines have both anti-inflammatory and bronchodilator
effects, and likewise are sometimes used early in exacerbations
to accelerate recovery, reduce breathlessness and improve sputum
clearance.
Exacerbations in bronchiectasis are often mediated by bacteria,
hence antibiotics (oral, nebulised or intravenous) are almost always
prescribed. The spectrum of bacteria responsible for exacerbations
in bronchiectasis is not the same as for other respiratory diseases
such as chronic obstructive pulmonary disease (COPD); therefore,
antibiotic choice should preferably be guided by knowledge of a
person’s previous sputum cultures (Pasteur 2010).
Non-pharmacological interventions
Chest clearance techniques are used during exacerbations, both
self-administered and given by physiotherapists, especially where
inpatient treatment is required (Pasteur 2010).
Why it is important to do this overview
The purpose of a Cochrane overview is to compile evidence sys-
tematically from a range of reviews of interventions for the same
disease or condition into a single comprehensive and user-friendly
document (Becker 2011).
A number of therapeutic interventions are currently available for
themanagement of bronchiectasis includingpharmacological, sur-
gical and physical therapy-based treatments. Clinical guidelines
for management of the condition have highlighted a paucity of
good-quality evidence with which to inform treatment choices
and clinical decision-making (Pasteur 2010). There are currently
20 bronchiectasis reviews on The Cochrane Library and there is a
need to present a clear and accessible synthesis of this evidence for
users, clinicians and policy-makers. This overview will document
the evidence for the efficacy, safety and tolerability of the range of
interventions covered by the reviews. Analysis of the evidence will
provide a basis for recommendations for future clinical trials and
Cochrane reviews. The overview will also enable an assessment of
reported outcomes that may be used to inform a set of standard
outcomes for future research studies.
O B J E C T I V E S
To provide an overview of the efficacy and safety of interventions
for adults and childrenwith bronchiectasis fromCochrane reviews.
To identify gaps in the evidence base that will inform recommen-
dations for new research and reviews, and
To summarise information on reported outcomes and make rec-
ommendations for the reporting of standard outcomes in future
trials and reviews.
M E T H O D S
6Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Criteria for considering reviews for inclusion
Types of reviews
We included non-CF bronchiectasis reviews published in the
Cochrane Database of Systematic Reviews (CDSR) regardless of
whether they included a clinical trial. We included Cochrane re-
views of RCTs and controlled clinical trials (CCTs, such as quasi-
controlled trials). In order to ensure comprehensive and up-to-
date coverage of the evidence base, we also searched for and con-
sidered primary clinical trials.
Types of participants
We included reviews of adults and children with physician or
radiographically diagnosed non-CF bronchiectasis. Ideally, we
planned to include only studies with diagnoses based on HRCT,
but, since this overview is based on Cochrane reviews, we were
led by their inclusion criteria and discussed the limitations of the
inclusion criteria where this arose. Although we recognised that
treatments for adults and children may vary, we included evidence
for both because the majority of reviews have done so, but pre-
sented data for adults and children separately where possible. We
scanned inclusion criteria of included studies to confirm that re-
views did not contain a substantial proportion of people with CF.
We planned to include trials of people with stable bronchiectasis
and people experiencing an exacerbation; however, we only found
reviews in stable bronchiectasis.
Types of interventions/comparisons
We included all interventions for bronchiectasis and divided them
into the following subgroups to provide structure for the evidence
synthesis.
Pharmacological interventions
• Antibiotics.
• Vaccines.
• Bronchodilators.
• Anti-inflammatory medication.
• Bronchodilator and anti-inflammatory combination
medication.
• Mucous clearance agents.
Non-pharmacological interventions
• Physiotherapy - airway clearance techniques (ACT);
pulmonary rehabilitation; physical training techniques.
• Disease management and education - education; nurse
specialist management.
• Surgery - lobectomy, pneumonectomy, lung
transplantation.
• Other - interventions for massive haemoptysis; oxygen
therapy; ventilation (e.g. continuous positive airway pressure
(CPAP), bilevel positive airway pressure (BPAP)); pulmonary
hypertension management; nutrition.
We described diagnostic criteria and trial duration for each in-
cluded review. We reported trials that included concomitant med-
ications or complex interventions according to the original review.
Types of outcome measures
Primary outcomes
• Exacerbations measured as frequency, proportion of people
with one or more exacerbations, or duration of exacerbations.
• Lung function measured as forced expiratory volume in one
second (FEV1) in litres or as per cent of predicted.
• QoL using measures validated in a clinical setting.
Secondary outcomes
• Symptoms (e.g. dyspnoea, cough, wheeze).
• Sputum characteristics (volume and validated sputum
colour tool).
• Adverse events (e.g. haemoptysis).
• Hospitalisation.
• Mortality.
We tabulated the range of outcomes used in the reviews.
Search methods for identification of reviews
We searched the CDSR on The Cochrane Library (Issue 2, 2015).
We applied no date or language restrictions applied (see Appendix
1 for the search strategy).
We searched the Cochrane Airways Group trials register on 11
February 2015 using the search term ’bronchiectasis’ to identify
trials that were not included in reviews. The register contains
trial reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED
and PsycINFO, and handsearching of respiratory journals and
meeting abstracts.
Data collection and analysis
Selection of reviews and trials
Two overview authors (EJW, SS) reviewed the results of the search
and obtained full-text Cochrane reviews for further scrutiny.
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One overview author (EJW) reviewed the search for new primary
studies, excluding duplicates and those already included in re-
views. We tabulated relevant trials and the author team evaluated
them for inclusion in the overview. We added relevant RCTs on
bronchiectasis to the evidence map (Table 1), and graded each
intervention as either ’high’ or ’low’ priority based on appraisal of
the evidence by the clinical author team (SF and DE).
Data extraction and management
Twooverview authors (EJW, SS) extracted and tabulated data from
included reviews. We resolved disagreements by consensus. We
extracted the following data:
• assessment of methodological quality;
• diagnostic criteria;
• study duration;
• details of study participants;
• interventions;
• comparisons;
• outcomes and time points.
We presented data in a series of summary tables. We planned to
extract information on the definition of exacerbations used in the
reviews but there was not scope to include it in the overview. We
planned to contact review authors for additional information not
reported in the original reviews.
Assessment of methodological quality of included
reviews
Methodological quality of included reviews
Two overview authors (EJW, SS) independently assessed the
methodological quality of included reviews using the ’assess-
ment ofmultiple systematic reviews’ (AMSTAR) instrument (Shea
2007; Appendix 1). We planned to conduct sensitivity analyses
to explore the consequences of synthesising reviews of differing
quality, but reviews were generally of high quality and therefore
there was no basis for a sensitivity analysis.
Quality of evidence in included reviews
We planned to summarise the quality of the evidence in included
reviews that themselves included studies in the ’Summary of Find-
ings’ and ’Risk of Bias’ tables according to the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
approach and recommendations in the Cochrane Handbook of
Systematic Reviews of Interventions, respectively (Balshem 2011;
Higgins 2011).
Data synthesis
We presented data as a narrative synthesis supported by tables of
statistical outcomes reported in the original reviews. The compar-
isons presented were determined by data in the included reviews.
Although we had planned to update Cochrane reviews with new
studies identified for inclusion, we did not do this because the
scope of a number of the reviews requires modification before they
are updated.
In order to reflect and prioritise clinical decision-making in the
overview, we summarised the evidence using an evidence map,
incorporating Cochrane reviews and RCTs not yet included in
the reviews (Table 1). These were set in the context of practice
recommendations using the BTS guidelines for bronchiectasis (
Pasteur 2010).
We grouped data by intervention and outcome against the follow-
ing framework: pharmacological interventions (antibiotics, vac-
cines, bronchodilators, anti-inflammatories, bronchodilators and
anti-inflammatories combinations, mucous clearance agents); and
non-pharmacological interventions (physiotherapy, disease man-
agement and education, surgery, other interventions).
We tabulated the evidence separately (post-hoc) for each of our
planned outcomes and classified them by consensus taking into
account the BTS/Scottish Intercollegiate Guidelines Network
(SIGN) bronchiectasis guidelines (Pasteur 2010). The following
classifications are listed in the tables under ’Evaluation’:
• no evidence of benefit - no statistically significant or
clinically relevant effect;
• evidence of statistical benefit - statistically significantly
effect in favour of intervention;
• evidence of statistical benefit but not clinically relevant
change - as above but magnitude of effect below published
threshold of minimum clinically important difference (MCID)
for the outcome, where available (MCID listed in table footnote);
• evidence of clinically relevant benefit - as point 2. above and
mean effect of MCID or greater;
• evidence of harm - statistically significant effect in favour of
control;
• unclear - conflicting evidence of effects.
Summary of the evidence base
We analysed and discussed limitations in the evidence base, in-
cluding the number of participants and overall methodological
quality of the reviews, and this informed recommendations for
future research and Cochrane reviews.
Reliability of the outcomes
We planned to examine heterogeneity of the evidence for each
primary outcome in the overview by summarising the range of the
I2 statistic variation. We planned to evaluate the role and relevance
of each outcome measure critically by comparing the sensitivity
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and stability of measures across the tranche of reviews to inform
recommendations for a core set of outcomes for future studies.
Subgroup analysis
We categorised the review by pharmacological and non-pharmaco-
logical interventions in order to aid interpretation, imposed clin-
ically relevant structure on the review and compared outcomes
by diagnostic technique. We planned to analyse studies of adults
(aged 19 years and older) and children (aged 18 years and younger)
separately.
Sensitivity analysis
We planned to conduct sensitivity analyses for methodological
quality based on GRADE criteria, by comparing results from all
studies with the results following exclusion of low-quality studies.
R E S U L T S
Results of the search
The search of The Cochrane Library Issue 2, 2015 identified 25
records for Cochrane reviews. We excluded four reviews for the
following reasons (Figure 2): one review was withdrawn (Jones
2011); one was in people with cough rather than bronchiectasis
(Marchant 2005), one was a protocol (McCullough 2014), and
one was the protocol for the present overview (Welsh 2013).
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Figure 2. Study flow diagram.
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We included 21 reviews but extracted data from, and rated the
quality of, only nine reviews that reported results for people with
bronchiectasis alone (Bradley 2002; Evans 2007; French 2003;
Goyal 2014; Hart 2014; Kapur 2009; Lee 2013; Wilkinson 2014;
Wurzel 2011). Of the reviews with no usable data, two reviews in-
cluded studies withmixed clinical populationswhere datawere not
reported separately for people with bronchiectasis (32% of partici-
pants inPizzutto 2010 and12%of participants inChang 2009 had
bronchiectasis only) and the remaining 10 reviews contained no
any trials (Chang 2007; Corless 2000; Franco 2003; Irons 2010;
Kapur 2007; Lasserson 2001a; Lasserson 2001b; Sheikh 2001;
Steele 2000; Warburton 2000).
In total, the search identified 645 references. We identified 46
studies that could be included in Cochrane review updates or in
new Cochrane reviews.
Description of included reviews
We presented a table of the main characteristics of the included
reviews (see Table 2).
Study design
Nine reviews included RCTs. Approximately two-thirds of trials
were parallel group designs while the remaining one-third were
cross-over studies. The studies ranged from single session to year-
long studies. Each review included from one to 11 trials and 40
individual studies were included in the overview. Seventy per cent
(28) of the trials in the overview included 40 or fewer participants.
The total number of participants included in reviews ranged from
40 (Goyal 2014) to 1040 (Hart 2014).
Included participants
Of the 40 studies included across the reviews, three (nine to 34
participants) included children. Where reported in the included
reviews, in studies reporting an age range, the age of adults ranged
from 36 to 73 years and children ranged from six to 16 years, and
in studies reporting mean ages, the mean age ranged from 50 to
70 years and in one study of children and adolescents the mean
age was 13 years. The proportion of male participants ranged from
21% to 72%. Where reported, mean baseline FEV1 ranged from
1.17 L to 1.66 L and from 47% to 88% predicted.
Diagnosis of bronchiectasis in included trials
Three reviews defined inclusion criteria as a clinical diagnosis of
non-CF bronchiectasis, two reviews specified radiographic diag-
nosis and four reviews specified radiographic or clinical diagnosis,
or both.
Interventions
We mapped the Cochrane reviews onto the framework of inter-
ventions specified in our protocol (Welsh 2013) in Table 1 cover-
ing the two broad classes of pharmacological and non-pharmaco-
logical interventions.
Pharmacological interventions
There were 17 reviews on pharmacological interventions.
• Two separate reviews for inhaled hyperosmolar agents and
mucolytics, treatments that aim to ease expectoration (Hart
2014; Wilkinson 2014), both contained trials.
• One review compared long-acting beta2-agonists (LABA)
and inhaled corticosteroids (ICS) combination with ICS alone
(Goyal 2014), and contained trials.
• Two reviews on antibiotics, one on short-term courses
(Wurzel 2011), and one on long-term therapy (Evans 2007),
both contained trials.
• Five reviews on anti-inflammatory treatments: ICS (Kapur
2009); oral corticosteroids (Lasserson 2001b), leukotriene
receptor antagonists (Corless 2000), and non-steroidal anti-
inflammatory drugs (Kapur 2007; Pizzutto 2010). Only the ICS
review included any trials.
• Four reviews on bronchodilators compared with placebo,
covering short-acting beta2-agonists (SABA) (Franco 2003),
LABA (Sheikh 2001), anticholinergics (Lasserson 2001a), and
xanthines (Steele 2000). These reviews did not include any trials.
• One review on influenza vaccines (Chang 2007), one on
pneumococcal vaccines (Chang 2009), and one on surgery for
bronchiectasis (Warburton 2000) did not include any trials.
Non-pharmacological interventions
There were four reviews on non-pharmacological interventions:
• One review on ACT (Lee 2013), one on physical training
(Bradley 2002), and one on management strategies for
bronchiectasis comparing nurse- versus doctor-led care (French
2003), all contained trials.
• One review on singing for bronchiectasis did not include
any trials (Irons 2010).
Methodological quality of included reviews
Quality of included reviews
An overview of methodological quality using the AMSTAR tool
is in Appendix 3. All nine reviews that included trials provided:
an a priori design as a published Cochrane protocol; duplicate
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study selection and data extraction; comprehensive search of the
Cochrane Airways Group specialised register and searches of grey
literature. All reviews contained tables of included and excluded
studies and rated study quality, though they did not all use the latest
Cochrane ’Risk of bias’ tool (Higgins 2011). Eight of the nine re-
views incorporated study quality in their conclusions. One review
did not identify whether randomisation sequence generation was
adequate (French 2003). Six reviews that included study synthesis
used appropriate methods to combine studies. There were too few
trials in any reviews to enable assessment of publication bias by
a funnel plot. All reviews included conflict of interest statements.
One review included a trial conducted by one or more authors of
the review (French 2003).
Quality of evidence in included reviews
The reviews used various tools to assess the quality of the evidence
or risk of bias (Table 3). Three reviews assessed the risk of bias
using the Jadad scale (a composite scale of five points in which five
is the best protected against bias); one review awarded a score of 1/
5 (Bradley 2002), one awarded 3/5 (French 2003), and one gave
4/5 or 5/5 (Evans 2007). Seven reviews incorporated a Cochrane
risk of bias assessment and review authors judged most of the
studies to contain a mixture of high, low and unclear risk of bias.
The review comparing inhaled LABA/ICS combination with ICS
alone included a study described as blinded, but judged inadequate
following correspondence with the trial authors. Blinding was not
possible for trials in the ACT and nurse- versus doctor-led care
reviews.
Four reviews contained a ’Summary of findings’ table. Three re-
views judged the outcomes reported in the ’Summary of findings’
table to be low quality (Goyal 2014; Lee 2013; Wilkinson 2014),
while one review on hyperosmolar agents judged the evidence to
be of moderate quality (Hart 2014).
There were a number of incidences of poor reporting in the re-
views. For example, one review did not report the number of par-
ticipants in studies and another had more extensive reporting is-
sues including inadequate ’Characteristics of included studies’ ta-
bles and reporting of outcome data. These issues were reported
back to the author teams responsible for updating the reviews.
Overall, the quality of the evidence was limited by lack of high-
quality studies in the included reviews. Furthermore, where there
was more than one study, it was often not possible to pool results
due to heterogeneity in either the treatment or the outcomes. For
example, FEV1 was reported as a difference in absolute end-of-
trial point estimates, as per cent of predicted point estimates, as
differences in change from baseline (litres or % predicted) and as
annual decline rates, with some change analyses not controlling for
baseline variation. The quality of reporting was also variable with
some comparisons described as ’significant’ and others reported as
mean difference (MD) but without measures of spread (e.g. stan-
dard deviation (SD)) or precision (confidence interval (CI)), and
some comparisons reported only in terms of statistical significance
(P value). The variation may be attributable to poor reporting in
the original trials, the review, or both.
Effect of interventions
We present a series of tables including data for each outcome
from the included reviews (see Table 4; Table 5; Table 6; Table 7;
Table 8; Table 9; Table 10). We summarise the information from
reviews that contribute data to each outcome below. Comparisons
are versus placebo unless otherwise stated.
Primary outcome: exacerbation
Nine reviews included exacerbations as an outcome measure (
Table 4). Evaluation in column 6 of Table 4 is based on reference
values for MCID shown in the table footnote. Trials included in
the reviews on short-term antibiotics (Wurzel 2011) and physical
therapy (Bradley 2002) did not report exacerbation data. Of the
12 comparisons covered by the seven reviews with exacerbation
outcomes, 10 were each based on a single trial and seven of those
trials included 40 or fewer participants.
Pharmacological interventions
Impact of long-term antibiotics on exacerbations was unclear (
Evans 2007). One small study reported a significant reduction of
31% in exacerbations requiring antibiotics (12 participants, five
events versus 16 events, P value = 0.019) but three larger studies
reported no significant reduction in exacerbation frequency (odds
ratio (OR) 0.96, 95% CI 0.27 to 3.46, 120 participants, 2 trials;
MD -0.4, P value = 0.33, 30 participants, 1 trial, Evans 2007).
The impact of hyperosmolar agents was also unclear. The review
reported a statistically significant and clinically relevant reduction
in annual exacerbation rate with hypertonic saline (HTS) com-
pared with isotonic saline, based on one small study (2.14 with
hypertonic saline versus 4.85 with isotonic saline, P value < 0.05,
30 participants, Hart 2014), but a similar study reported no sig-
nificant benefit for the same comparison (values not reported, 40
participants, Hart 2014). One large study in the same review re-
ported no significant benefit with mannitol (risk ratio (RR) 0.92,
95% CI 0.78 to 1.08, 461 participants, Hart 2014).
Themucolytics review reported a significantly higher exacerbation
risk of 35%with RhDNase (2.5 mg) compared with placebo from
one moderately sized trial (RR 1.35, 95% CI 1.01 to 1.79, 176
participants, Wilkinson 2014). The trials comparing RhDNase 5
mg with placebo, bromhexine with placebo or erdosteine with no
intervention did not report exacerbations.
The ICS review showed no conclusive evidence of benefit. One
small study reported fewer exacerbations with ICS compared with
placebo (1 with fluticasone versus 3 with placebo, 24 participants,
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Kapur 2009), but there were too few events to draw firm conclu-
sions. Two larger studies in the same ICS review reported no sig-
nificant reduction in exacerbation frequency over six or 12months
(MD 0.09, 95% CI -0.61 to 0.79, 57 participants; MD -0.49,
95% CI -1.49 to 0.51, 86 participants, Kapur 2009).
The review of LABA/ICS combination versus ICS included one
small study showing no significant reduction in the proportion of
people experiencing an exacerbation (four with LABA/ICS versus
seven with ICS, 40 participants) but this was based on a small
number of events and significance values were not reported (Goyal
2014).
Non-pharmacological interventions
There was no significant reduction in participant-reported exac-
erbations for nurse specialist management compared with doctor-
led care based on one moderately-sized trial (MD 0.05, 95% CI -
1.07 to 1.17, 80 participants, French 2003). The review of ACTs
reported no significant reduction in risk of exacerbation based on
one small study of adults (RR 0.71, 95% CI 0.23 to 2.25, 20
adults, Lee 2013).
Primary outcome: lung function
Eight reviews reported FEV1. Table 5 summarises outcome data
and evaluation of benefit, based on reference values for MCID.
Of the 18 comparisons covered by the eight reviews with relevant
outcomes, 13 were each based on a single trial and 10 comparisons
included 40 or fewer participants. Trials included in the physical
therapy review did not report FEV1 data (Bradley 2002).
Pharmacological interventions
One review reported evidence of benefit. The ICS review reported
a significant, but not clinically relevant, difference in FEV1 (MD
0.09 L, 95% CI 0.03 to 0.15, P value = 0.002, 101 participants,
3 studies, Kapur 2009), but the effect was dependent on only one
trial without a placebo comparison. The MD of 90 mL was less
than the MCID reference value (100 mL in COPD), indicating a
clinically unimportant change for the majority of people.
Two reviews reported unclear evidence of benefit. The inhaled
hyperosmolar review reported a statistically significant and clini-
cally relevant benefit for FEV1 %predicted with hypertonic saline
compared with isotonic saline (MD 13.3%, P value < 0.01, 30
participants, 1 study) but not for FEV1 L (MD 0.19 L, 95% CI -
0.37 to 0.75, P value = 0.5, 40 participants, 1 trial, Hart 2014).
There was no evidence of benefit formannitol versus placebo based
on three trials (372 participants, Hart 2014). The mucolytics re-
view also reported inconclusive evidence of benefit. The review
reported a statistically significant and clinically relevant increase
with erdosteine for FEV1 L (MD 200 mL, 95% CI 40 to 360, 30
participants, 1 trial), but not for FEV1 % predicted in the same
trial (MD4.5%, 95%CI -3.11 to 12.11) (Wilkinson 2014). There
was conflicting evidence of benefit for RhDNase 2.5 mg, with one
trial showing no difference and one showing a more rapid decline
in FEV1 (MD 2.10%, 95% CI -4.05 to -8.25; MD -1.9%; 237
participants, 2 trials), and there was no evidence of benefit from
trial of the RhDNase 5 mg dose (40 participants). There was no
evidence of benefit for bromhexine compared with placebo (MD
184.00 mL, 95% CI -149.75 to 517.75, 88 participants, 1 trial)
(Wilkinson 2014).
The two antibiotics reviews showed no evidence of benefit in FEV1
based on four small trials of long-term antibiotics (study power
unclear) (86participants, Evans 2007) andone trial of short-course
antibiotics (74 participants, Wurzel 2011).
The inhaled LABA/ICS combination review reported no evidence
of benefit for FEV1, based on one small trial (study power unclear)
(MD -14.00 mL, 95%CI -84.14 to 56.14, 40 participants, 1 trial,
Goyal 2014).
Non-pharmacological interventions
TheACTs review reported a statistically significant benefit inFEV1
for children (difference 8.86%, 9 children, 1 trial) but not for
adults (MD 0.0 L, P value = 0.7, 38 adults, 3 trials), though values
were not clearly reported (Lee 2013).
The review of nurse-led care reported no evidence of benefit, based
on one trial (MD 2.37, 95% CI -7.37 to 12.11, 80 participants,
1 trial, French 2003).
Primary outcome: quality of life
Nine reviews included QoL as an outcome measure but none of
the trials included in the short-term antibiotics review (Wurzel
2011), the ICS review (Kapur 2009), or the mucolytics review
(Wilkinson 2014) reported QoL data. Of the nine comparisons
covered by the six reviews with QoL data, five were each based on a
single trial and five comparisons included 43 or fewer participants.
Table 6 summarises outcome data and evaluation of benefit, based
on reference values for MCID.
Pharmacological interventions
The inhaled hyperosmolar review reported significantly lower St.
George’s Respiratory Questionnaire (SGRQ) scores (i.e. better
QoL) with mannitol (MD -2.05, 95% CI -3.69 to -0.40, 840
participants, 3 studies, Hart 2014). However, the effects of hyper-
tonic saline were unclear, showing evidence of clinically relevant
improvement in Bronchiectasis Quality of Life (QoL-B) scores
(MD -11.6, SD 17.7; P value = 0.03) but conflicting evidence for
SGRQ (2 trials) and Leicester Cough Questionnaire (LCQ) scores
(2 trials).
The effects of LABA/ICS combination on QoL were unclear.
There was no statistically significant improvement in SGRQ total
scores (MD -4.57, 95%CI -12.38 to 3.24, 40 participants, 1 trial)
but there was insufficient information to judge whether the study
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was underpowered (risk of type II error), and theMDexceeded the
four unit threshold for clinically important change (Goyal 2014).
The long-term antibiotics review reported no evidence of benefit
in SGRQ total scores, but the power of this study to detect an
effect was also unclear (MD -0.07, 95% CI -3.69 to 3.55, 30
participants, 1 trial, Evans 2007).
Non-pharmacological interventions
Two reviews reported evidence of clinically relevant benefit. The
physical therapy review reported significantly better QoL, using
the Chronic Respiratory Questionnaire (CRQ) (MD 12.4, 95%
CI 2.38 to 22.43, P value = 0.015, 43 participants, 2 trials), that
exceeded the MCID threshold (0.5 units) (Bradley 2002). The
ACTs review reported better QoL of both statistical and clinical
significance, based on the SGRQ and LCQ outcome measures in
one small study (SGRQ median difference 8.5, P value = 0.005;
LCQmedian difference 1.3, P value = 0.002; 20 participants, Lee
2013).
The nurse specialist management review reported no evidence of
benefit in SGRQ scores (MD -1.70, 95% CI -10.00 to 6.60, 80
participants, 1 trial, French 2003).
Secondary outcome: symptoms
Eight reviews included symptoms as an outcome measure (Table
7), but trials in four of those reviews did not report relevant data
(Bradley 2002; Evans 2007; Lee 2013; Wurzel 2011), and one
review did not include symptoms as an outcome measure (French
2003). The eight comparisons reported in the four reviews with
symptom data were each based on a single trial.
Pharmacological interventions
The ICS review reported evidence of clinically relevant reduction
in dyspnoea using the Transition Dyspnea Index (TDI) (OR 3.33,
95%CI 1.17 to 9.43, 62 participants, 1 trial, Kapur 2009), but no
evidence of benefit for wheeze in the same trial (OR 0.87, 95%CI
0.31 to 2.44, 62participants, 1 trial). The LABA/ICS combination
review also reported evidence of clinically relevant reduction in
dyspnoea using the TDI, for people on the combination inhaler
(MD 1.29, 95% CI 0.40 to 2.18, 40 participants, 1 trial), and
significantly more cough-free days (MD 12.3%, 95% CI 2.38 to
22.2), based on the same small trial (Goyal 2014).
The inhaled hyperosmolar review reported no evidence of ben-
efit in symptoms or cough in the same single mannitol trial
(Bronchiectasis Symptoms Questionnaire, MD -1.20, 95% CI -
3.91 to 1.51; Leicester Cough Questionnaire, MD 0.00, 95% CI
-0.81 to 0.81, 343 participants) and no evidence of benefit for
hypertonic saline (no values, P value > 0.16, 40 participants, 1
trial) (Hart 2014).
The mucolytics review reported a significantly lower cough score
at the end of the bromhexine trial (MD -0.48, 95% CI -0.89 to -
0.06, 88 participants, 1 trial, Wilkinson 2014).
Non-pharmacological interventions
Symptoms were not reported in trials included in the physical
therapy or ACTs reviews (Bradley 2002; Lee 2013), and not in-
cluded as an outcome in the nurse specialist management review
(French 2003).
Secondary outcome: sputum characteristics
Eight reviews included one or more sputum characteristics as an
outcome measure (Table 8), but trials included in three reviews
did not report data (Bradley 2002; Goyal 2014; Wurzel 2011),
and one review did not include sputum as an outcome measure
(French 2003). Fifteen trials reported sputum outcomes and 11 of
those trials included 40 or fewer participants. A total of 13 sputum
outcome comparisons were reported, with nine comparisons each
based on a single trial.
Pharmacological interventions
The long-term antibiotics review reported significantly lower spu-
tum leukocyte and purulence scores in one small paediatric trial
(values not reported, P value < 0.01, 27 children, Evans 2007),
and significantly reduced sputum volume in another small pae-
diatric trial (values not reported, P value = 0.0001, 34 children).
Impact of antibiotics on sputum reduction in adults was less clear,
with one small trial reporting no significant difference in sputum
volume (median difference 1mL, P value not reported, 12 adults).
Sputum outcomes were not reported in the trial included in the
short-term antibiotics review (Wurzel 2011).
In the ICS review, two trials of less than six months’ duration
reported significantly lower daily sputum volume (MD -8.30 mL,
95% CI -16.55 to -0.05, 93 participants, 1 trial; and no values,
P value = 0.003; 20 participants, 1 trial). One longer trial (12
months) reported no difference in sputum volume or purulence
(volume, values not reported; purulence, MD 0.2, 95% CI -0.94
to 1.34, 89 participants). Sputum outcomes were not reported in
the trial included in the LABA/ICS combination review (Goyal
2014).
The impact of inhaled hyperosmolar agents was largely unclear
(Hart 2014). Two small studies reported a significant reduction
in sputum volume for people receiving mannitol (MD 21.9%, CI
not reported, P value < 0.001, 14 participants; MD 22.3%, CI
not reported, P value < 0.0001, 11 participants) but a larger study
reported a significant difference in sputum weight in favour of
placebo (MD 4.32 g, 95% CI 1.60 to 7.04, 362 participants), but
benefits from the larger study were attributed to higher antibiotic
frequency in the placebo group. Hypertonic saline was associated
with higher sputumweight than isotonic saline (median difference
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2.13 g, P value not reported, 24 participants) but significance of
the effect was unclear.
The mucolytics review reported no significant difference in spu-
tum purulence for people receiving RhDNase (MD 0.28, 95%
CI -0.04 to 0.60, 40 participants, 1 trial, Wilkinson 2014). There
was no significant difference in volume production (scored on 0 to
2 scale) for people receiving erdosteine (MD 0.40, 95% CI -0.03
to 0.83, N = 30, 1 trial) and the significance of the difference in
sputum volume in one bromhexine trial was unclear (MD -21.5%
change at end of trial, 95% CI -38.9 to -4.1, 88 participants, 1
trial).
Non-pharmacological interventions
The review of ACTs reported a significant increase in sputum vol-
ume for people receiving the intervention, based on two small
studies (MD 8.4 mL, 95% CI 3.4 to 13.4, 8 participants, 1 trial;
MD 3 mL, P = 0.02, 20 participants, 1 trial) and sputum weight,
based on two small studies (MD 17 g, P value < 0.01, 8 partici-
pants, 1 trial; MD 24 g, P value < 0.05, 10 participants, 1 trial)
(Lee 2013).
Trials in the review of physical therapy did not report sputum
outcomes (Bradley 2002), and the review of nurse-led care did not
include sputum production as an outcome (French 2003).
Secondary outcome: adverse events
Adverse events were reported in six reviews (see Table 9).
Pharmacological interventions
The review of long-term courses of antibiotics reported no signif-
icant difference in withdrawals (Peto OR 1.06, 95% CI 0.42 to
2.65, 260 participants, 5 trials), cases of diarrhoea (Peto OR 2.47,
95% CI 0.91 to 6.71, 148 participants, 2 trials) or rash (Peto OR
1.94, 95% CI 0.19 to 19.47, 54 participants, 2 trials). However
there were more cases of wheeze (Peto OR 8.56, 95% CI 1.63
to 44.93), dyspnoea (Peto OR 4.41, 95% CI 1.43 to 13.61) and
chest pain (Peto OR 8.84, 95% CI 1.88 to 41.50) in one trial
(74 participants) of nebulised antibiotics (Evans 2007). One adult
study in the short-term antibiotics review reported no difference in
adverse events (OR 2.24, 95%CI 0.86 to 5.82, 74 adults) (Wurzel
2011).
There were more adverse events with LABA/ICS combination
compared with ICS alone (37 events with ICS, 12 events with
LABA/ICS) but it was unclear whether the unit of analysis was
the number of events or the number of people experiencing one
or more event (Goyal 2014). The review of ICS monotherapy did
not report adverse events (Goyal 2014).
In the review of hyperosmolar agents, there was no significant
difference in adverse or serious adverse events for mannitol (873
participants, 3 trials) or hypertonic saline (59 participants, 2 trials)
(Hart 2014).
The review of mucolytics reported no significant difference in ad-
verse events with bromhexine (88 participants, 1 trial, Wilkinson
2014). There was no significant difference in adverse events with
RhDNase 5 mg (40 participants, 1 study) except for more cases
of influenza, but data were unclear as values were not reported
(Wilkinson 2014). Significantly more cases of elevated antibodies
were reported with RhDNase 2.5 mg (OR 28.19, 95% CI 3.77
to 210.85, 176 participants, 1 trial). Data on adverse events were
not reported for erdosteine.
Non-pharmacological interventions
The review of ACTs reported no adverse events or withdrawals
(Lee 2013).
The physical therapy review did not report adverse events (Bradley
2002), and the review of nurse-led care did not include adverse
events (French 2003).
Secondary outcome: hospitalisations
Five reviews reported data on hospitalisation (Table 10).
Pharmacological interventions
The review of long-term antibiotics reported evidence of benefit
in a reduced rate of admissions in one small trial (MD -1.9, P value
= 0.023, 17 adults, 1 trial) and reduced number of admissions in
another small trial (MD -0.6, P value = 0.038, 30 adults, 1 trial,
Evans 2007). The review of short-term antibiotics did not include
hospitalisations as an outcome (Wurzel 2011).
The review of LABA/ICS combination therapy reported no sig-
nificant difference in number of admissions (OR 0.26, 95% CI
0.02 to 2.79, 40 participants, 1 trial, Goyal 2014).
The trial in the review of ICS monotherapy did not report hospi-
talisations (Kapur 2009).
The review of hyperosmolar agents reported no evidence of benefit
with mannitol versus placebo (461 participants, Hart 2014), and
the evidence for hypertonic saline was unclear (40 participants,
Hart 2014).
The review of mucolytics reported no evidence of benefit with
RhDNase 5 mg (40 participants, Wilkinson 2014), Trials on
bromhexine or erdosteine did not report hospitalisations.
Non-pharmacological interventions
The review of nurse-led care reported no evidence of benefit in
number of hospitalisations (RR 1.59, 95% CI 0.75 to 3.39, 80
participants, 1 trial, French 2003).
The reviews of physical therapy or ACTs did not report hospital
admissions.
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Secondary outcome: mortality
Three reviews reported data on mortality (Evans 2007; Goyal
2014; Hart 2014), and the remaining reviews either did not in-
clude mortality outcomes (Bradley 2002; Wurzel 2011), or the
outcome was not reported in the included trials (French 2003;
Kapur 2007; Lee 2013; Wilkinson 2014) (Table 11).
Pharmacological interventions
The review of long-term antibiotics reported no evidence of harm
(Peto OR 0.57, 95% CI 0.07 to 4.54, 128 adults, 2 studies, Evans
2007), though this was based on only four events.
The review of LABA/ICS combination included one small trial
(40 participants) in which there were no deaths (Goyal 2014).
The review of inhaled hyperosmolar agents reported two deaths
in one large mannitol trial that were unrelated to the intervention
and no deaths in two smaller trials (25 participants). The four
small hypertonic saline trials reported no deaths (113 participants)
(Hart 2014).
Non-pharmacological interventions
Trials included in the nurse-led care (French 2003) and ACTs (Lee
2013) reviews did not report mortality outcomes and the review of
physical therapy did not include mortality as an outcome measure
(Bradley 2002).
Evidence map
We present an overview of the evidence for non-CF bronchiectasis
in Cochrane reviews, trials and BTS guideline recommendations,
togetherwith recommendations forCochrane reviews and research
priorities (Table 1).
The level of evidence for treatments for bronchiectasis in the BTS
guideline was variable (Pasteur 2010). There were relatively few
trials in bronchiectasis, reviews without data or with inadequate
data, and guidelines based on low-quality evidence. The evidence
base for bronchiectasis is broadly lacking in large, high-quality
RCTs that provide robust evidence to inform clinical practice.
We make the following recommendations for Cochrane reviews:
New reviews needed
• Long-term courses of antibiotics for bronchiectasis (Evans
2007) should be separated into two new reviews: one on
macrolides and one on antibiotics that should also include
rotating antibiotics as a separate comparison.
• Replace the two reviews on mucolytics (Wilkinson 2014)
and inhaled hyperosmolar agents (Hart 2014) with a single
review on mucolytics for bronchiectasis and include a subgroup
analysis on inhaled versus oral mucolytics.
Changes to existing reviews
• Short-term course of antibiotics (Wurzel 2011): expand
scope to include head-to-head trials (i.e. one antibiotic compared
with another antibiotic) and dual antibiotic trials (more than one
antibiotic administered at once). Include inpatients versus
outpatients as a subgroup analysis.
• Expand the review on SABA to include head-to-head trials
(Franco 2003).
• Expand the review on LABA to include head-to-head trials
(Sheikh 2001).
• Refocus the review on physical training as pulmonary
rehabilitation (Bradley 2002).
• Add head-to-head trials of chest clearance techniques to the
ACT review (Lee 2013).
D I S C U S S I O N
Summary of main results
We examined the evidence from published reviews for the treat-
ment of non-CF bronchiectasis (in adults and children) in this
overview. While we have been able to document the published
evidence, it was not possible to draw definitive conclusions from
published results with respect to a range of clinically relevant is-
sues. The primary outcomes of our overview were exacerbations,
lung function and QoL.
A small number of trials on long-term antibiotics and hyperos-
molar agents reported a reduction in exacerbation rate but the
overall evidence was conflicting and inconclusive. RhDNase was
associated with an increased risk of exacerbation. There was no
evidence of benefit from ICS, nurse-led care or ACTs. The impact
of LABA/ICS combination on exacerbations was unclear.
Improvements in lung functionwere reported for ICSbut evidence
for impact of hyperosmolar agents and mucolytics was conflicting
and inconclusive. There was no evidence of benefit for short-term
antibiotics and nurse-led care and unclear evidence for long-term
antibiotics, ACTs and LABA/ICS combination.
Improvements in QoL were reported for ACTs and physical ther-
apy but benefit for hyperosmolar agents was conflicting and in-
conclusive. There was no evidence of benefit for nurse-led care and
the evidence for long-term antibiotics and LABA/ICS was unclear.
Secondary outcomes were poorly reported in trials included in
the reviews. Small studies on ICS therapy and LABA/ICS combi-
nation therapy reported improvements in dyspnoea, wheeze and
cough-free days. One small bromhexine study also reported im-
provements in cough. ACTs reduced in sputum volume, but evi-
dence for long-term antibiotics, ICS and hyperosmolar agents was
conflicting and inconclusive. Long-term antibiotics and RhDNase
increased adverse events and long-term antibiotics were also as-
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sociated with fewer admissions to hospital. No reviews reported
differences in mortality.
Many comparisons reporting no significant evidence of benefit
were based on single small trials, or unpooled combinations of
small trials, where power of the trials to detect an effect was unclear.
The clinical impact of statistically significant differences between
comparison groups was also unclear for many outcomes as refer-
ence points (MCID) for clinical interpretation were not available.
Overall completeness and applicability of
evidence
We highlighted a number of evidence gaps, as outlined in Table
1. There were relatively few reports of high-quality trials in
bronchiectasis and many trials were small, with fewer than 40 par-
ticipants, and potentially unable to detect an effect. Trial popula-
tions were relatively narrow and extrapolation of findings to the
wider bronchiectasis population may be limited. Furthermore, all
trials were conducted in stable bronchiectasis rather than during
exacerbations.
We also identified opportunities for new Cochrane reviews and
updates of existing reviews, to summarise the evidence base better.
Therefore, this overview summarised the available evidence and
highlighted the need for new evidence reviews and new research.
Pharmacological interventions
Antibiotics
The evidence base for long-term antibiotics suggests that there
may be some benefits but further research is required to clarify
remaining uncertainty (Evans 2007).
Areas of uncertainty yet to be explored in Cochrane reviews in-
clude longer-term macrolide use, P aeruginosa colonisation (ver-
sus other sputum microbiology - such as Haemophilus influenzae)
and emerging antibiotic resistance. In particular, while previous
studies may have suggested that antibiotic resistance is not an issue
for sputum microbiology among those individuals not colonised
withP aeruginosa on long-term treatment, some caution is advised.
Furthermore the emergence of other non-P aeruginosa colonising
species in people on longer-term antibiotics (including bacteria
not previously thought to be clinically relevant - often with re-
sistance patterns), is also a concern. Patterns of resistance for P
aeruginosa remain an issue and the benefits of oral/inhaled pro-
phylaxis for these people continues to be unresolved. Therefore, a
balanced clinical approach considering the possible benefits aris-
ing from transition of sputum purulence to mucoid with lessened
symptoms needs to be weighed against the limited available evi-
dence.
The use of macrolides has attracted attention following the discov-
ery that these drugs may exert effects through both antibacterial
and immunosuppressive (anti-inflammatory) effects (King 2007).
Therefore, macrolide use remains a matter of clinical judgement
on a case-by-case basis without definitive evidence in favour and
a Cochrane review is needed.
The role of antibiotics in the management of bronchiectasis is
unclear, with Cochrane reviews unable to support their prescrip-
tion conclusively (Evans 2007; Wurzel 2011). There have been
no trials on treating exacerbations with antibiotics, though this
is a commonly used intervention. Future research into the use of
long-term antibiotics might separately address people colonised
and not colonised with pseudomonas, in particular with respect
to the use of macrolides.
Bronchodilators, anti-inflammatory medication and
combination therapy
Despite the lack of evidence of benefit in the overview for ICS
and bronchodilators, their use is widespread in bronchiectasis. The
BTS national audits surveyed secondary and tertiary care prac-
tice in the UK and reported findings based on 1460 and 2404
people seen in outpatient departments over a two-month period
in 2010 and 2011 respectively (Hill 2012). Of these, approxi-
mately 80%were using regular ICS, 67%using SABAand64%us-
ing LABA, and 10% short-acting and 30% long-acting anti-mus-
carinics. The BTS guidelines suggest ICS/bronchodilator therapy
should be used only where there is co-existent asthma, although
this is unlikely to account solely for such high use seen in the
audit (Hill 2011). Other potential reasons may include a previ-
ous misdiagnosis of bronchiectasis as asthma or COPD, with peo-
ple remaining on medications even after the correct diagnosis has
been made. The risk-benefit of these medications is unknown in
bronchiectasis, but ICS may raise particular concerns as their use
has been associated with an increased risk of pneumonia inCOPD
and it is possible that this risk is even greater in bronchiectasis,
especially in people with severe disease (Singh 2009).
ICS monotherapy may improve lung function and reduce dysp-
noea; however, therewas no conclusive evidence of benefit for exac-
erbations. LABA/ICS combination may reduce dyspnoea, wheeze
and cough, but there was no significant reduction in exacerba-
tions and impact on QoL was unclear. These outcomes were based
on a small number of studies in review of ICS and LABA/ICS
combination. ICS are widely prescribed, but this practice is not
currently supported by robust evidence in bronchiectasis. A large,
high-quality clinical trial is needed to investigate their role, ideally
with stratification to allow for assessment of the subgroup with
physiological or inflammatory (or both) evidence of asthma.
Mucolytic agents
We considered two reviews studying a range of mucolytic agents
(carbocysteine, erdosteine, mannitol, hypertonic saline, bromhex-
ine and RhDNase) (Hart 2014; Wilkinson 2014). The reviews
17Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
reported inconclusive results, with sporadic and minimal bene-
ficial effects for agents such as hypertonic saline (exacerbations),
erdosteine (FEV1) and mannitol (QoL), but no overall persua-
sive evidence of efficacy for any of the mucolytic drugs in key ar-
eas of bronchiectasis management. Findings suggest some concern
for the use of RhDNase in non-CF bronchiectasis given isolated
study data suggesting an increase in exacerbations and influenza.
No concerns over adverse effects were raised for other treatments,
though there wereminimal data.While these results have not been
substantiated in further trials, at this stage caution is advised.
Non-pharmacological interventions
Physiotherapy - airway clearance techniques, pulmonary
rehabilitation, physical training techniques
Respiratory physiotherapy has several potential roles in bronchiec-
tasis: airway mucous clearance, pulmonary rehabilitation and
physical training.
Airway clearance is a cornerstone of current therapy in bronchiec-
tasis (Pasteur 2010), and there are several theoretical mechanisms
of benefit. For example, effective clearance of sputum might be
expected to: improve breathlessness and QoL by clearing blocked
airways; decrease the microbial and inflammatory burden and,
thus, reduce airways damage and exacerbation frequency; and im-
prove airway deposition of inhaled drugs. The review summarised
here did indeed show that airway clearance improved disease-spe-
cific QoL (SGRQ), cough symptoms (LCQ) and sputum produc-
tion, based on five small studies (55 participants) (Lee 2013). It is
perhaps unsurprising that there were few data available to inform
guidelines; it may arguably now be unethical to perform a sham-
controlled trial of chest clearance in people with clinically signif-
icant disease. However, there are trial results available comparing
methods of chest clearance (e.g. Eaton 2007; Naraparaju 2010;
Paneroni 2011; Patterson 2005; Su 2012; Syed 2009; Thompson
2002; Venturelli 2012), and this would be a worthwhile focus for
a future Cochrane review. Novel methods should undergo equiv-
alence trials versus current practice before being recommended for
use.
At the time of writing the Cochrane overview, there were no spe-
cific trials of pulmonary rehabilitation in bronchiectasis (Bradley
2002). Since then, pulmonary rehabilitation (with or without in-
spiratory muscle training) has been shown to improve exercise ca-
pacity and QoL (Newall 2005), and is recommended in the BTS
guidance for people with bronchiectasis and breathlessness affect-
ing daily activities (Pasteur 2010). Data have since emerged to
support further the impact of pulmonary rehabilitation on QoL
and exercise tolerance in bronchiectasis (Mandal 2012), and also
suggest a reduction in exacerbation rate over the subsequent 12
months (Lee 2014).
Disease management and education
Only one study to date has addressed the impact of specialist-nurse
versus doctor-led care, and it found no difference in exacerbation
rate, FEV1 or QoL (French 2003). The sample size calculation in
the sole included study was “on the basis of establishing equiv-
alence of nurse practitioner led care and doctor led care”, so it
would not have been powered to identify a difference. There are a
few trials in patient education and self management (e.g. Lavery
2011), and we would suggest that this is prioritised as a future
review topic, especially as bronchiectasis is a condition that is not
widely recognised in the general population, yet has significant
impacts on daily QoL and is often associated with exacerbations
and hospitalisations, all of which could potentially be improved by
better patient understanding and self management (Lavery 2007)
Surgery, other
Limited data were available to guide when surgery should be con-
sidered in bronchiectasis and there were no trials in the Cochrane
review (Warburton 2000). Sham-controlled studies are unlikely to
be performed, and cases where surgery may be considered by the
treating clinicians are rare such that an RCT would be unlikely
to recruit sufficient numbers of people. The current recommen-
dations by the BTS are that surgery may be considered in people
with poorly controlled localised disease or where there is massive
haemoptysis (as an alternative to bronchial artery embolisation)
(Pasteur 2010).
Coverage and quality of bronchiectasis trials
The survey of the literature and the BTS guidelines in
Table 1 revealed that the evidence base for interventions for
bronchiectasis is poor. There are some bronchiectasis trials in
progress, we looked for ongoing trials on bronchiectasis at
www.clinicaltrials.gov on the 12 February 2015 and there were
two trials on the inhaled antibiotic tobramycin (NCT01677403;
NCT02102152); four trials on the inhaled antibiotic cipro-
floxacin (NCT01515007; NCT01764841; NCT02104245;
NCT02106832); one trial on POL7080, an antibiotic active
against P aeruginosa (NCT02096315); and one trial of long-term
ACTs (NCT02324855). One protocol for a study on 10-valent
pneumococcal-Haemophilus influenzae protein D conjugate vac-
cine for preventing exacerbations was returned in the search for
trials (O’Grady 2013). However, there are only 500 references for
controlled trials on bronchiectasis on CARG and over half of the
Cochrane reviews on bronchiectasis contain no trials. Many of
the recommendations in the BTS/SIGN guidelines are necessarily
based on evidence from non-RCTs and expert opinion (Pasteur
2010). Guidelines and current clinical practice are, in places,
based on extrapolating treatments from asthma, COPD and CF
bronchiectasis to bronchiectasis. For example, bronchodilators are
used to treat people with bronchiectasis on the basis that they have
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shown to be beneficial for people with asthma, but there have
been no trials to show that they are safe and effective. Currently,
in bronchiectasis, based on this overview, there lacks a solid foun-
dation to inform good clinical practice and informed patient de-
cision-making. There are limited data available in children, with
only three paediatric trials (number of children = nine to 34).
Quality of Cochrane reviews on bronchiectasis
Authors of some overviews of Cochrane reviews in other disease
areas have revisited the original study reports to supplement data
reported in theCochrane reviews (e.g.Cahill 2013 used study-level
data to perform network meta-analyses, Cates 2012 updated the
literature search of all included reviews). However, we decided to
focus on summarising the evidence and issuing recommendations
for new and revised Cochrane reviews.
Clinical guidelines and Cochrane reviews are closely intertwined.
Guidelines frequently rely on Cochrane reviews to underpin spe-
cific recommendations. We have drawn heavily on the BTS guide-
line (Pasteur 2010) to help us map the evidence available for
bronchiectasis and to highlight gapswheremore trials or Cochrane
reviews are needed or to highlight gaps in the reviews themselves.
To best inform guidelines, our Cochrane reviews should aim to
cover the relevant clinical questions and this overview shows no-
table gaps in review topics for bronchiectasis. We suggest that
overviews can be used by CRGs to assess individual disease areas.
Quality of the reviews
The quality of the reviews was considered on two levels; the qual-
ity of the selection of the Cochrane reviews (i.e. the coverage of
the possible trials) and the quality of the reviews themselves. To
assess the coverage of the available evidence, we used the frame-
work developed for the protocol to this overview to map the cur-
rently available evidence from Cochrane reviews, trials and the
BTS guideline (Table 1). We added our judgements on the impli-
cations for Cochrane (e.g. whether a Cochrane review should be
expanded or where a new review is needed).
Eight out of 21 reviews had search dates of over 5 years old and
19 out of 21 reviews had search dates of over two years old.
The reviews scored highly on the AMSTAR scale (reviews scored
9/10 to 10/10), but on several occasions we found several issues
in reviews that would require us to revisit the trial reports and that
may necessitate updating of the Cochrane review, which is beyond
the scope of this overview. For instance, the hospital admission
data were unclear in French 2003; the total number of admissions
was reported together with the number of re-admissions and it
would be helpful to have some explanation of this information.
Development of a tool to appraise the quality of Cochrane re-
views based on the Methodological Expectations of Cochrane In-
tervention Reviews (MECIR) standards may be beneficial to fu-
ture overviews.
While the reviews scored from 9/10 to 10/10 using the AMSTAR
tool, we had problems in finding enough data from the Cochrane
reviews to complete our overview in a few cases. We urge the
incorporation of the MECIR standards as a minimum for all new
and updated reviews on The Cochrane Library.
Only four reviews contained a ’Summary of findings’ table and
a GRADE evaluation of the evidence. We felt that a GRADE
evaluation of the evidence would require a significant amount
of work, which would be necessary at the review level and is,
therefore, beyond the scope of this overview. However, due to
the paucity of consistent evidence from high-quality trials in the
reviews, we believe that further evidence is likely to change our
confidence in the effect of all the treatments. We recommend that
’Summary of findings’ tables are completed in future updates of the
Cochrane reviews in line with Cochrane Airways Group editorial
policy.
Potential biases in the overview process
We identified potentially eligible studies by screening all trials
coded as bronchiectasis and added these to Table 1. It is possible
that this list is incomplete and furthermore specific searches would
be done for each systematic review or update.
We included only Cochrane reviews and there may be other sys-
tematic reviews on interventions for bronchiectasis published out-
side of The Cochrane Library, but we are unable to comment on
that.
Agreements and disagreements with other
studies or reviews
One systematic review andmeta-analysis on inhaled antibiotics for
bronchiectasis, published in 2014, included 12 trials with 1264
adults (Brodt 2014). The trials were on the following antibiotics
and included some of the inhaled antibiotics that would be in-
cluded in an update of the Cochrane antibiotics reviews:amikacin,
aztreonam, ciprofloxacin, gentamicin, colistin and tobramycin.
The review included trials of between four weeks’ and 12 months’
duration. The review showed that antibiotics reduced bacterial
load and the risk of acute exacerbations, and both antibiotic and
placebo groups had the same withdrawal rate due to adverse ef-
fects. The authors concluded that “Inhaled antibiotics may pro-
vide an effective suppressive antibiotic therapy with an acceptable
safety profile in adult patients with stable non-CF bronchiectasis
and chronic bronchial infection” (Brodt 2014).We did not update
the antibiotics reviews, so some of this evidence in missing from
this overview. Funders looking at this overview to make decisions
about trials to fund, should consider the more recent antibiotics
trials before making a decision.
One economic analysis of long-term humidification therapy in
people with COPD or bronchiectasis concluded that therapy was
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“moderately cost-effective for patients with moderate to severe
chronic obstructive pulmonary disease or bronchiectasis” and that
it met thresholds for funding in New Zealand (Milne 2014).
We found three systematic reviews published on macrolide ther-
apy. One review included nine RCTs on 530 participants and
showed that long-term macrolides compared with placebo/usual
care reduced the risk of exacerbations, dyspnoea and 24-hour spu-
tum volume; improved QoL and slowed the decline in lung func-
tion (FEV1) (Wu 2014). Another review of nine trials on 559
participants concluded, “Macrolide maintenance therapy, both in
adults and children, was effective and safe in reducing bronchiec-
tasis exacerbations, but not the admissions for exacerbations. In
addition, macrolide administration in adults was associated with
improvement inQoL and spirometry, but not 6MWT[six-minute
walking test]” (Gao 2014a). Another review on four studies con-
cluded, “Macrolide maintenance therapy was effective in reducing
pulmonary exacerbations, and improving lung function in adults
withNCFB [non-CFbronchiectasis].However, it did not improve
QoL, and could have led to macrolide resistance” (Zhuo 2014).
The conclusions were stronger than in the Cochrane review, but
the non-Cochrane reviews were more up-to-date including newer
trials.
A review on mucolytics for children with bronchiectasis found no
studies on children,which agreeswith the findings of theCochrane
review (Snijders 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The key findings of this overview, in terms of the major outcomes
that we felt were most important in people with bronchiectasis,
were as follows:
• long-term antibiotics may reduce sputum production,
frequency of exacerbations and hospitalisation, but may also be
associated with more frequent adverse events (wheeze, dyspnoea
and chest pain);
• inhaled corticosteroid monotherapy may improve lung
function but the effect is small;
• bromhexine may reduce cough, but evidence of benefit for
hyperosmolar agents and mucolytics is generally unclear;
• airway clearance techniques may reduce sputum production
and improve quality of life;
• RhDNase is associated with more frequent exacerbations;
• long-acting beta2-agonsts/inhaled corticosteroid
combination therapy may reduce dyspnoea, wheeze and cough;
• 70% of trials in the reviews included in the overview were
small (40 or fewer participants), which limits interpretation.
Implications for research
We believe that research should focus on measuring exacerbations,
quality of life and, in longer-term trials, lung function. Future
studies must be powered to detect differences and adverse events
should be rigorously reported. More research should be under-
takenwith children either separately or reported separately in stud-
ies with combined populations.
A national or international organisation for bronchiectasis should
be established, with patient values at its core, to support the design
and development of high quality pragmatic trials that will serve to
improve the evidence base. Useful work could include evaluation
of the need for a bronchiectasis-specific quality of life measure,
and development of a core set of outcome measures for future
research.
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Table 1. Evidence map
Intervention Cochrane
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(number of par-
ticipants)
Potential new
studies1
BTS guideline
recom-
mendation (evi-
dence grade: A-
D)
Overview team
recom-
mendations for
new Cochrane
reviews, or
changes to ex-
isting reviews
Overview team
suggested re-
search priorities
based on evi-
dence presented
in this evidence
map
Pharmacological interventions
Antibiotics Long term
(Evans 2007)
9 (378) Altenburg 2013;
Anthony 2014;
Chen
2013; Haworth
2014; Liu 2012;
Lourdesamy
2014;
Murray 2011;
Rogers 2014
(aka Serisier
2013a); Serisier
2013b;
Valery 2013;
Wilson 2013a;
Wong 2012
- Recommended
for people with
≥ 3 exacerba-
tions per year
requiring antibi-
otics or exacerba-
tions causing sig-
nificant morbid-
ity (C). Start on
low dose (C), de-
termine regimen
by sputum mi-
crobiology (neb-
ulised C and oral
D)
- Insufficient ev-
idence for: long-
term quinolones
Separate review
for macrolides
High
1. Targeted an-
tibiotic treat-
ment for coloni-
sation or re-
current infection
with the same or-
ganism (e.
g. Pseudomonas,
Haemophilus)
2. Non-targeted
macrolide treat-
ment
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Table 1. Evidence map (Continued)
(C), macrolides
(C)
- No ev-
idence: children,
rotational antibi-
otics
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(Wurzel 2011)
1 (74) Antoniu 2013;
Barker 2014;
Chang 2013; De
Diego 2013
- Recom-
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dose specific an-
tibiotics (B to C)
. If no previous
bacte-
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treatment amox-
icillin 500 mg 3
x daily (B) or
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- IV antibiotics
consid-
ered for people
resistant to ther-
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- Antiviral drugs
not recom-
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ingly (D)
Expand
to include head-
to-head trials
Low
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Table 1. Evidence map (Continued)
SABA
(Franco 2003)
0 Ding 2006 Update re-
view. Expand to
include head-to-
head trials
Low
Anticholiner-
gics
(Lasserson
2001a)
0 None identified Update when
new trials
Low
Anti-inflamma-
tory medication
ICS
(Kapur 2009)
6 (276) Ding 2006;
Hernando 2012
Not rec-
ommended rou-
tinely for adults
(B) or chil-
dren (D) except
for concomitant
asthma
Update review High
1. Validate rou-
tine prescription
of ICS
2. Stratify by re-
versibility
OCS for acute
exacerbations
(Lasserson
2001b)
0 None identified No evidence Update if new
trials
High
LTRA
(Corless 2000)
0 None identified Not recom-
mended (D)
Update if new
trials
Low
Inhaled
NSAIDs
(Pizzutto 2010)
0 None identified Not recom-
mended (D)
Update if new
trials
Low
Oral NSAIDs
(Kapur 2007)
0 None identified Not recom-
mended (D)
Update if new
trials
Low
Oral methylx-
anthines
(Steele 2000)
0 None identified Not rec-
ommended rou-
tinely (D)
Update if new
trials
Low
Combination
bronchodilator
and anti-inflam-
matory medica-
tion
LABA/ICS
combination
(Goyal 2014)
1 (40) None identified None for combi-
nation
None Low (pending
ICS trials)
Mucous
clearance agents
Inhaled hyper-
osmolar
(Hart 2014)
11 (927) None identified May be consid-
ered (B)
Combine the 2
reviews and sub-
group: inhaled
vs. oral
High
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Table 1. Evidence map (Continued)
Mucolytics
(Wilkinson
2014)
4 (528) Bilton 2014 Trials of mu-
colytics required
(U). RhD-
Nase not recom-
mended (A and
D)
High
Intervention Cochrane
review
Number of in-
cluded studies
(number of par-
ticipants)
New studies BTS guideline
recom-
mendation (evi-
dence grade; A-
D)
Recom-
mendations for
Cochrane
reviews
Priority for re-
search
Non-pharmacological interventions
Physiotherapy PR/exercise
therapy
(Bradley 2002)
2 (52) Bernabeu 2014;
Gurses
2013; Lee 2014;
Mandal 2012,
Newall 2005;
Ong 2001
- Recom-
mended: PR for
ADL-re-
lated breathless-
ness (B)
- IMT with re-
habilitation for
maintenance of
effect (B)
Low priority for
updating
Low
ACTs
(Lee 2013)
5 (38) Bernabeu 2014;
Eaton 2007;
Liaw 2011;
Mandal 2012;
Murray 2009;
Naraparaju
2010; Nicolini
2013; Paneroni
2011;
Patterson 2004;
Patterson 2005;
Su 2012;
Syed 2009;
Tambascio
2011;
Thompson
2002; Tsang
2003; Venturelli
2012
- Should be con-
sidered: active
cycle of breath-
ing (B), oscil-
lating PEP de-
vices (A). Auto-
genic drainage,
PEP or gravity-
assisted methods
if other tech-
niques not effec-
tive, appropriate
or acceptable (D)
. Manual tech-
niques can
be added dur-
ing acute exacer-
bation (D)
- No evidence
on who benefits
most
Update and ex-
pand to include
head-to-head tri-
als
High
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Table 1. Evidence map (Continued)
Disease manage-
ment and educa-
tion
Nurse-led care
(French 2003)
1 (80) Lavery 2011
Liaw 2011
Successful man-
agement of peo-
ple with asthma
and COPD in
primary care by
well-trained
nurses and GPs
provides
model for devel-
opment of better
care for people
with bronchiec-
tasis. People with
bronchiectasis
should as a mini-
mum be referred
to a chest physi-
cian, physiother-
apist and respira-
tory nurse with
expertise in the
condition
Low priority for
updating
Low for nurse-
led care, since
care now deliv-
ered by multidis-
ciplinary teams
Self
management of
exacerbations is
medium priority
Communication
strategy
- Yang 2012 - - -
Surgery Surgery
(Warburton
2000)
0 None identified Con-
sider for people
with poorly con-
trolled localised
disease (D). Po-
tential first-line
therapy for mas-
sive haemoptysis
(D)
Update if new
trials
Low (RCTs un-
likely)
Other Singing
(Irons 2010)
0 Maa 2007
(acupuncture)
- NIV can im-
prove QoL in
some
people with con-
comitant
chronic respira-
tory failure (D)
- No evidence:
lung transplanta-
tion
Update of re-
view on singing
deemed unnec-
essary’. Extrapo-
late evidence on
complementary
therapies
from asthma and
COPD reviews
Low
Statins n/a Mandal 2014 Not included in
guideline
- -
31Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Evidence map (Continued)
Neutrophil elas-
tase inhibitors
n/a Stockley 2013 - - -
Immunostimu-
lating agents
n/a Gao 2014b;
Pavord 2013
- - -
Humidification
of air
- Milne 2014 - - -
1. These studies may be included in future Cochrane reviews.
Abbreviations: ACT: airways clearance technique; ADL: activities of daily living; aka: also known as; COPD: chronic obstructive
pulmonary disease; GP: general practitioners; ICS: inhaled corticosteroids; IMT: inspiratory muscle training; IV: intravenous; LABA:
long-acting beta2-agonist; LTRA: leukotriene receptor antagonist; N: number of studies; n/a: not applicable; NIV: non-invasive
ventilation;NSAID: non-steroidal anti-inflammatory drug;OCS: oral corticosteroids; PEP: positive expiratory pressure; PR: pulmonary
rehabilitation; QoL: quality of life; RCT: randomised controlled trial; RhDNase: recombinant human deoxyribonuclease I; SABA:
short-acting beta2-agonists; U: ungraded.
Table 2. Characteristics of included reviews
Review (search date*) Intervention dose
(number of studies)
Comparison Number studies, de-
sign, duration
Study participants -
treatment, n, baseline
FEV1, age, gender
Pharmacological interventions
Antibiotics (long term)
(Evans 2007)
(Jan 2011)
Chil-
dren: oral clarithromycin
15 mg/kg/day (1); oral
roxithromycin 4 mg/kg
twice/day (1)
Adults: neb-
ulised tobramycin 300
mg twice/day (2); in-
haled tobramycin 100
mg twice/day (1); oral
amoxicillin 3 g twice/
day (1); oral azithromy-
cin 500 mg twice/day (1)
; oral erythromycin 500
mg twice/day (1); oral
oxytetracycline 500mg4
times/day (1)
6 placebo
3 usual care
9 RCTs: 7 double-blind
(including 1 cross-over)
; 2 open-label (including
1 cross-over)
Duration: 4 weeks to 1
year
Children: n = 61, FEV1
not stated, mean age 13
years, 52-56% male
Adults: n = 317, mean
FEV1 50-83%
predicted, mean age 50-
70 years, 50-64% male
Antibiotics (short-
term)
(Wurzel 2011)
(Feb 2011)
Nebulised tobramycin
600 mg/day
Placebo 1 RCT: double-blind
Duration: 4 weeks
n = 74, FEV1 not stated,
mean age 65 years, 39%
male
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Table 2. Characteristics of included reviews (Continued)
ICS
(Kapur 2009) (Oct
2010)
Beclomethasone: 800
mcg/day (1), 1500 mcg/
day (1)
Fluticasone propionate:
500 vs. 1000 mcg/day
(1), 1000 mcg/day (3)
5 placebo
1 nothing
6 RCTs: double-blind
Duration 4 weeks to 1
year
Beclomethasone: n = 40,
mean age 50 years, 40-
55% male
Fluticasone propionate:
n = 263, mean age 51-70
years, 34-72% male
Baseline FEV1 not stated
LABA/ICS
combination
(Goyal 2014)
(Mar 2014)
Budesonide 640 mcg/
day + formoterol 18
mcg/day
Budesonide 1600 mcg/
day
Open-label
Duration: 3 months
n = 40, mean FEV1 61%
predicted, mean age 70
years, 45% male
Inhaled hyperosmolar
(Hart 2014)
(Apr 2014)
Man-
nitol: dose unknown (1)
, 480 or 320 mg (1), 400
mg (3), 320 mg (1), 300
mg (1) per day
HTS 6% vs. ITS 7% (2)
per day
5 placebo
2 nothing
4 dose comparison
11RCTs: 7 double-blind
(includes 3 cross-overs);
2 single blind (includes 1
cross-over); 2 open-label
cross-overs
Duration: 4 days to 1
year
Mannitol;
n = 927, mean FEV1 62-
88% predicted, age 52-
63 years; 21-36% male
HTS:
n = 113, mean FEV1
57-82%predicted,mean
age 57-61 years, 29-50%
male
Mucolytics
(Wilkinson 2014)
(Jan 2010)
Oral bromhexine 30 mg
twice/day (1); nebulised
RhDNase 2.5 mg twice/
day (2); oral erdosteine
225 mg twice/day (1)
Sin-
gle or repeat doses alone
or combined with: glu-
cocorticosteroids, beta2-
agonists or xanthines
Placebo 4 RCTs: 3 double-blind;
1 open-label
Duration: 15 days to 24
weeks
Bromhexine: (30 mg in
1st week): n = 88, mean
FEV1 1.66 L, mean age
52 years, 64% male
RhDNase:
n = 410, mean FEV1 51-
58% predicted, age 53-
60 years, 38-46% male
Erdosteine: n = 30, mean
FEV1 47% predicted,
mean age 70 years, 70%
male
Review (search date) Intervention, dose
(number of studies)
Control Number of studies, de-
sign, duration
Study participants -
treatment, n, baseline
FEV1, age, gender
Non-pharmacological interventions
PR/exercise therapy
(Bradley 2002)
(Feb 2005)
IMT: (1) + PR (1) 1 no treatment
1 sham IMT/PR or no
treatment
Unblinded RCT
Duration: 8 weeks
n = 52, FEV1 not stated,
mean age 60-62 years,
gender not stated
ACTs
(Lee 2013)
(Oct 2012)
Children: oscillating PEP
with flutter (1)
Adults: oscillat-
2 PEP vs. sham PEP
1 PEP vs. no interven-
tion
5 cross-over RCTs
Duration: single session
- 6 months
PEP: Adults:
n = 38, mean FEV1 53-
76% predicted, age 47-
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Table 2. Characteristics of included reviews (Continued)
ing PEP with flutter (2)
or acapella (1)
Postural drainage + FET
(1)
1 PEP vs. PD vs control
1 PD + FET vs. resting
73 years Children: n = 9,
FEV1 not stated, age 6-
16 years
PD: n = 8, mean FEV1
1.17 L, age 36-71 years
Gender not stated
Nurse-led care
(French 2003)
(Jul 2008)
Nurse-led Doctor-led care 1 cross-over RCT
Duration: 1 year each
arm
n = 80, mean FEV1 70%
predicted, mean age 58
years, 31% male
Abbreviations: ACT: airway clearance technique; FET: forced expiratory technique; FEV1: forced expiratory volume in 1 second;
HTS: hypertonic saline; ICS: inhaled corticosteroids; IMT: inspiratory muscle training; ITS: isotonic saline; LABA: ; n: number
of participants; PD: postural drainage; PEP: positive expiratory pressure therapy; PR: pulmonary rehabilitation; RCT: randomised
controlled trial; RhDNase: recombinant human deoxyribonuclease I; vs: versus.
* Date the most recent literature search was fully incorporated into the review (month and year).
Table 3. Quality of the evidence in included reviews
Review Summary of findings Quality assessment
tool
Risk of bias Comments
Pharmacological interventions
Antibiotics (long term)
(Evans 2007)
No Yes Jadad = 4/5 or 5/5 Allocation concealment
only, mixture of unclear
and low RoB
-
Antibiotics (short
term)
(Wurzel 2011)
No No Allo-
cation concealment un-
clear, but study blinded.
6 participants withdrew
from placebo group due
to need for another an-
tibiotic
-
ICS
(Kapur 2009)
No No Allocation concealment
unclear. Most studies
blinded. Follow-up over
90% in half of studies. 1
study included only peo-
ple with reversible air-
flow obstruction, which
biased results towards
people with an asthma
component
-
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Table 3. Quality of the evidence in included reviews (Continued)
LABA/ICS
combination
(Goyal 2014)
Yes, low-quality evidence
(QoL, TDI, cough-free
days, HA/exacerbations)
No High RoB due to inad-
equate blinding and un-
clear randomisation pro-
cedures
-
Inhaled hyperosmolar
(Hart 2014)
Yes. Moderate-quality
evidence
No Mostly unclear. 5 trials
had issues with randomi-
sation procedure
-
Mucolytics
(Wilkinson 2014)
Yes. Bromhexine: low-
quality ev-
idence (AEs symptoms,
FEV1); RhDNase: low-
quality evidence (HA,
symptoms, FEV1); er-
dosteine: low-quality ev-
idence (mucous produc-
tion, FEV1)
No Mixed judgements -
Non-pharmacological interventions
PR/exercise therapy
(Bradley 2002)
No Yes. Jadad = 1/5 Pre-dates RoB tool. Not
possible to blind the par-
ticipants or personal
Reported as abstracts
and randomisation pro-
cedures not reported.
Baseline imbalance af-
fected internal validity of
trials
ACTs
(Lee 2013)
Yes. Low-
quality evidence (exacer-
bations, QoL)
No RoB judgements mixed,
blinding of participants
and personnel not possi-
ble
Judgements mixed and
limited by small sample
size and inadequate re-
porting
Nurse-led care
(French 2003)
No Yes. Jadad = 3/5 Blinding of participants
and personal not
possible. Randomisation
method unclear
Possible carry over effect
since nowash-out period
between cross-over study
periods
Abbreviations: ACT: airway clearance technique; AE: adverse events; FEV1: forced expiratory volume in 1 second; HA: hospital
admission; PR: pulmonary rehabilitation; QoL: quality of life; RhDNase: recombinant human deoxyribonuclease I; RoB: risk of
bias; TDI: Transitional Dyspnoea Index.
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Table 4. Outcomes in Cochrane reviews - exacerbations
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result1
Evaluation1
Pharmacological interventions
Antibiotics (long
term) vs. placebo
(Evans 2007)
≥ 1 exacerbations 90 (2, adults)
30 (1, children)
Peto OR 0.96 (0.27
to 3.46), P value = 0.
95 (I2 = 71%)
NSD No evidence of ben-
efit
Mean exacerbations
per person
30 (1, adult) MD-0.4, SDnot re-
ported, P value = 0.
33
NSD No evidence of ben-
efit
Frequency of exac-
erbations requiring
antibiotics
12 (1, adult) 5 events vs. 16, P
value = 0.019, un-
clear whether ab-
solute frequency or
per person
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
Outcome not reported in trial
ICS vs. placebo/no
treatment
(Kapur 2009)
Mean exacerbations
per person
57 (1)
86 (1)
MD 0.09 (-0.61 to
0.79), P value = 0.8
MD -0.49 (-1.49 to
0.51), P value not
reported
NSD No evidence of ben-
efit
≥ 1 exacerbations 24 (1) FP = 1, placebo = 3,
too few events to es-
tablish benefit
Not reported Unclear
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
Frequency of exac-
erbations
40 (1) LABA/ICS = 4, ICS
= 7, P value not re-
ported
Unclear whether ab-
solute frequency or
per person
NSD No evidence of ben-
efit
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs.
placebo
Frequency: rate/
year
461 (1) RR 0.92 (0.78 to 1.
08), P value not re-
ported
NSD No evidence of ben-
efit
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Table 4. Outcomes in Cochrane reviews - exacerbations (Continued)
HTS vs. ITS fre-
quency: rate/year
30 (1) HTS 2.14
vs. ITS 4.85, MD 2.
71, CI not reported,
P value < 0.05
Statistically signifi-
cantly difference
Evidence of clini-
cally relevant benefit
HTS vs. ITS fre-
quency: rate/year
40 (1) Values not reported NSD No evidence of ben-
efit
Mucolytics vs.
placebo
(Wilkinson 2014)
Bromhexine vs. placebo: outcome not reported in trial
RhDNase 5 mg vs. placebo: outcome not reported in trial
RhDNase 2.5 mg
vs. placebo
Frequency: rate/
year
176 (1) RR 1.35 (1.01 to 1.
79) favoured
placebo
Risk of exacerbation
significantly higher
(35%) with RhD-
Nase
Evidence of harm
Erdosteine vs. nothing: outcome not reported in trial
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Outcome not reported in trial
Nurse-led vs. doc-
tor-led care
(French 2003)
Infective exacer-
bations (participant
reported): rate/year
80 (1) MD 0.05 (-1.07 to
1.17), P value not
reported
NSD No evidence of ben-
efit
ACTs vs. no treat-
ment
(Lee 2013)
Frequency: > 12
weeks
20 (1, adult) (PEP-
based ACT)
RR 0.71 (0.23 to 2.
25)
NSD No evidence of ben-
efit
1. Minimum clinically important difference: ≥ 11% reduction in exacerbation frequency (Chapman 2013) or difference of ≥ 1
exacerbations per year (Pellegrino 2005).
Abbreviations: ACT: airway clearance technique; CI: confidence interval; FP: fluticasone propionate; HTS: hypertonic saline; ICS:
inhaled corticosteroids; IMT: inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; MD: mean difference;
NSD: no statistically significant difference; OR: odds ratio, PEP: positive expiratory pressure therapy; RhDNase: recombinant human
deoxyribonuclease I; RR: risk ratio; SD: standard deviation; vs: versus.
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Table 5. Outcomes in Cochrane reviews - lung function
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result1
Evaluation1
Pharmacological interventions
Antibiotics (long
term) vs. placebo
(Evans 2007)
FEV1 % predicted
at end of trial
27 (1, children)
17 (1, adults)
MD -1.05% (-6.93
to 4.83), P value = 0.
7
NSD No evidence of ben-
efit
FEV1 (unit not re-
ported)
59 (3) Not pooled but all
reported no differ-
ence (values not re-
ported)
NSD No evidence of ben-
efit
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
To-
bramycin vs. placebo:
FEV1 % predicted
change from base-
line
74 (1, adults) MD and CI not re-
ported, tobramycin
-2.2%; placebo 1.
5%, P value = 0.41
NSD No evidence of ben-
efit
ICS vs. placebo/no
treatment
(Kapur 2009)
Short-term follow-
up
< 6 months: FEV1
L change from base-
line
101 (3, adults) MD 0.09 L (0.03 to
0.15), P value = 0.
002
Effect based
on 1 study without
placebo comparison
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
FEV1 mL change
from baseline
40 (1) MD -14.00 mL (-
84.14 to 56.14), P
value not reported
NSD No evidence of ben-
efit
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs. placebo:
FEV1 % predicted
change from base-
line
17 (1) MD 2.70% (-8.53
to 13.93), P value
not reported
NSD No evidence of ben-
efit
Mannitol vs. placebo
FEV1 L: at end of
trial
343 (1) MD 0.03 L (-0.10
to 0.16), P value not
reported
NSD No evidence of ben-
efit
Mannitol vs. placebo
FEV1: change (unit
not reported)
12 (1) Not reported NSD No evidence of ben-
efit
HTS vs. ITS: FEV1
% predicted change
from baseline
30 (1) MD 13.30%
(CI not reported), P
value < 0.01
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
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Table 5. Outcomes in Cochrane reviews - lung function (Continued)
Favoured HTS
HTS vs. ITS: FEV1
L at end of trial
40 (1) MD 0.19 L (-0.37
to 0.75), P value = 0.
5
NSD No evidence of ben-
efit
Mucolytics vs.
placebo
(Wilkinson 2014)
Bromhexine vs.
placebo: FEV1 mL at
end of trial
88 (1) MD 184.00 mL (-
149.75 to 517.75),
P value not reported
NSD No evidence of ben-
efit
RhDNase 5 mg vs.
placebo: FEV1 L %
change from base-
line
40 (1) MD 2.10% (-2.90
to 7.10), P value not
reported
NSD No evidence of ben-
efit
RhDNase 2.5 mg vs.
placebo: FEV1 L %
change from base-
line
237 (2) n = 197, MD -1.9%
decline, P value < 0.
05, favoured placebo;
n = 40, MD 2.10%
(-4.05 to -8.25), P
value not reported
Statistically signifi-
cant difference (1
trial)
NSD (1 trial)
Unclear
Erdosteine vs. noth-
ing: FEV1 mL
change from base-
line
30 (1) MD 200 mL (40 to
360), P value not re-
ported
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
Erdosteine vs. noth-
ing: FEV1 % pre-
dicted change from
baseline
30 (1) MD 4.50% (-3.11
to 12.11), P value
not reported
NSD No evidence of ben-
efit
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Outcome not reported in trial
Nurse-led vs. doc-
tor-led care
(French 2003)
FEV1 % predicted
at end of trial
80 (1) MD 2.37 (-7.37 to
12.11), P value not
reported
NSD No evidence of ben-
efit
ACTs vs no treat-
ment
(Lee 2013)
FEV1 L at end of
trial
38 (3, adults) Median difference
0.0 L, P value = 0.
7 (1 study, no values
for other 2 studies)
NSD No evidence of ben-
efit
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Table 5. Outcomes in Cochrane reviews - lung function (Continued)
FEV1 (unit not re-
ported) at end of
trial
9 (1, children) Dif-
ference 8.86% (val-
ues not reported), P
value not reported,
favoured ACT
Statistically signifi-
cant difference
Unclear
1. Nominimum clinically important difference for FEV1 in bronchiectasis. Reference values fromAmerican Thoracic Society/European
Respiratory Society recommendations as follows: change of at least 100 mL or change of ≥ 20% in short-term trials (of weeks of
duration) and ≥ 15% in long-term trials (≥ 1 year) (Pellegrino 2005).
Abbreviations:ACT: airway clearance technique;CI: confidence interval; FEV1 : forced expiratory volume in1 second;HTS: hypertonic
saline; ICS: inhaled corticosteroids; IMT: inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; n: number
of participants; MD: mean difference; NSD: no statistically significant difference; RhDNase: recombinant human deoxyribonuclease
I; vs: versus.
Table 6. Outcomes in Cochrane reviews - quality of life
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result1
Evaluation1
Pharmacological interventions
Antibiotics (long
term) vs. placebo
(Evans 2007)
SGRQ
Total: change from
baseline
30 (1, adults) MD -0.07 (-3.69 to
3.55), P value = 0.9
Did not control for
baseline values
NSD Unclear
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
Outcome not reported in trial
ICS vs. placebo/no
treatment
(Kapur 2009)
Outcome not reported in trial
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
SGRQ
Total: change from
baseline
40 (1) MD -4.57 (-12.38
to 3.24), P value not
reported
Exceeds MCID but
wide CI
NSD Unclear
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs. placebo
SGRQ
Total: change from
baseline
840 (3) MD -2.05 (-3.69 to
-0.40), P value = 0.
015
Favoured mannitol
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
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Table 6. Outcomes in Cochrane reviews - quality of life (Continued)
HTS vs. ITS
SGRQ: Symptoms,
Activity, impacts at
end of trial
70 (2) n = 40 (1 trial)
, SGRQ: Symptom,
MD 1.60 (-12.53 to
15.73), P value = 0.
8; SGRQ: Activity
MD 2.70 (-13.11 to
18.51), P value = 0.
7; SGRQ: Impacts
4.40 (-7.50 to 16.
30), P value = 0.4
n = 30 (1 trial)
, significant changes
reported but values
not reported
NSD (1 trial) Sta-
tistically significant
difference (1 trial)
Unclear
HTS vs. ITS
QoL-B: Respiratory
Symptoms (end-
point not reported)
19 (1) MD -11.6 (SD 17.
7); P value = 0.03
Exceeds MCID
threshold of 8 units
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
HTS vs. ITS
LCQ: Physical, Psy-
cho-
logical, Social (end-
point not reported)
59 (2) n = 19 (1 trial),
Physical, MD -0.8
(SD 0.9), P value =
0.01, benefits HTS
n = 40 (1 trial)
, Physical, MD -0.
20 (-0.95 to 0.55),
P value = 0.6; Psy-
chological, MD 0.
20 (-0.63 to 1.03), P
value = 0.6; Social,
MD -0.10 (-0.85 to
0.65), P value = 0.8
Statistically signifi-
cant difference (1
trial)
NSD (1 trial)
Unclear
Mucolytics vs.
placebo
(Wilkinson 2014)
Outcome not reported in trials
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
CRQ Total: change
from baseline
43 (2) MD 12.4 (2.38 to
22.43), P value = 0.
015
Exceeds
MCID threshold of
0.5 units
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
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Table 6. Outcomes in Cochrane reviews - quality of life (Continued)
Nurse-led vs. doc-
tor-led care (French
2003)
SGRQ Total: (end-
point not reported)
80 (1) MD -1.70 (-10.00
to 6.60), P value not
reported
NSD No evidence of ben-
efit
ACTs vs. no treat-
ment
(Lee 2013)
LCQ Total: (end-
point not reported)
20 (1, adults) Median differ-
ence 1.3 (CI not re-
ported), P value = 0.
002, favoured ACT
Meets
MCID threshold of
1.3 units
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
SGRQ Total: (end-
point not reported)
20 (1, adults) (same
as above)
Median differ-
ence 8.5, (CI not re-
ported), P value = 0.
005, favoured ACT
Exceeds MCID
threshold of 4 units
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
1. MCID values: CRQ > 0.5 units (Chauvin 2008); SGRQ > 4 units (Jones 2005); QoL-B ≥ 8 units (Quittner 2014); LCQ ≥ 1.3
units (Raj 2009).
Abbreviations: ACT: airway clearance technique; CI: confidence interval; CRQ: Chronic Respiratory Questionnaire; HTS: hypertonic
saline; ICS: inhaled corticosteroid; IMT: inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; LCQ:
Leicester Cough Questionnaire; MCID: minimally clinically important difference; MD: mean difference; n; number of participants;
NSD: no statistically significant difference; QoL-B: Quality of Life - Bronchiectasis; SD: standard deviation; SGRQ: St George’s
Respiratory Questionnaire; vs: versus.
Table 7. Outcomes in Cochrane reviews - symptoms
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result1
Evaluation1
Pharmacological interventions
Antibiotics (long
term) vs. placebo
(Evans 2007)
Outcome not reported in trial
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
Outcome not reported in trial
ICS vs. placebo/no
treatment
(Kapur 2009)
Dyspnoea: number
with no improve-
ment in TDI by end
of trial
62 (1) OR 3.33 (1.17 to 9.
43)
Favoured ICS
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
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Table 7. Outcomes in Cochrane reviews - symptoms (Continued)
Exceeds MCID
threshold of 1 unit
Wheeze: number
with regular (no def-
inition) wheeze by
end of trial
62 (1) OR 0.87 (0.31 to 2.
44)
NSD No evidence of ben-
efit
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
Cough-free
days: percentage by
end of trial
40 (1) MD 12.3% (2.38 to
22.2) P value not re-
ported
Favoured combina-
tion
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Dys-
pnoea: TDI, change
from baseline
40 (1) MD1.29 (0.40 to 2.
18)
Favoured combina-
tion
Exceeds MCID
threshold of 1 unit
Statistically signifi-
cant difference
Evidence of clini-
cally relevant benefit
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs. placebo:
Bronchiecta-
sis SymptomsQues-
tionnaire: score at
end of trial
343 (1) MD -1.20 (-3.91 to
1.51) P value not re-
ported
NSD No evidence of ben-
efit
Mannitol vs. placebo:
LCQ: score at end
of trial
343 (1) MD 0.00 (-0.81 to
0.81)
P value not reported
NSD No evidence of ben-
efit
HTS vs. ITS:
Cough: VAS fre-
quency at trial end-
points
40 (1) No difference at 3,
6 or 12 months (val-
ues not reported), P
value > 0.16
NSD No evidence of ben-
efit
Mucolytics vs.
placebo
(Wilkinson 2014)
Bromhexine vs.
placebo:
Cough score (no de-
tail) (endpoint not
reported)
88 (1) MD -0.48 (-0.89 to
-0.06),
P value not reported
Favoured bromhex-
ine
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Outcome not reported in trial
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Table 7. Outcomes in Cochrane reviews - symptoms (Continued)
Nurse-led vs. doc-
tor-led care
(French 2003)
Not an outcome in the review
ACTs vs. no treat-
ment
(Lee 2013)
Outcome not reported in trial
1. Minimum clinically important difference for Transition Dyspnoea Index > 1 unit in COPD (Pellegrino 2005); LCQ ≥ 1.3 units
(Raj 2009).
Abbreviations: ACT: airway clearance technique; CI: confidence interval; HTS: hypertonic saline; ICS: inhaled corticosteroid; IMT:
inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; MCID: minimal clinically important difference;
MD: mean difference; NSD: no significant difference; OR: odds ratio; TDI: Transitional Dyspnoea Index; VAS: visual analogue scale;
vs: versus.
Table 8. Outcomes in Cochrane reviews - sputum characteristics
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result1
Evaluation1
Pharmacological interventions
Antibiotics (long
term) vs. placebo
(Evans 2007)
Sputum leuko-
cyte scores (end-
point and units not
reported)
27 (1, children) -0.52 (CI not re-
ported), P value < 0.
01
Favoured
antibiotics
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Sputum pu-
rulence scores (end-
point and units not
reported)
27 (1, children) -1.22 (CI not re-
ported), P value < 0.
01
Favoured
antibiotics
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Sputum volume
(endpoint not re-
ported)
12 (1, adults)
34 (1, children)
Adults: median dif-
ference 1 mL (val-
ues not reported), P
value not reported
Children: values not
reported, P value =
0.0001
NSD (1 trial) Sta-
tistically significant
difference (1 trial)
Unclear
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
Outcome not reported in trial
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Table 8. Outcomes in Cochrane reviews - sputum characteristics (Continued)
ICS vs. placebo/no
treatment
(Kapur 2009)
Sputum volume: < 6
months trial: mean
24 hour mL
113 (2) 1 study, n = 93: MD
-8.30 mL (-16.55 to
-0.05),
P value not re-
ported. Difference
described as ’trend’
1 study, n = 20: val-
ues not reported, P
value = 0.003
Favoured ICS
NSD (1 trial)
Statistically signifi-
cant difference (1
trial)
Unclear
Sputum volume: > 6
months trial: mean
24 hour mL
89 (1) Data not reported
in review because
skewed. Stated as
NSD
P value not reported
NSD No evidence of ben-
efit
Sputum purulence:
score (0-8 scale) at
end of trial (12
months)
89 (1) MD 0.2 (-0.94 to 1.
34)
P value not reported
NSD No evidence of ben-
efit
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
Outcome not reported in trial
Inhaled hyperosmo-
lar vs placebo or ITS
(Hart 2014)
Mannitol vs. placebo
Sputum weight: 24
hour change from
baseline
362 (1) n = 362, 1 trial, MD
4.32 g (1.60 to 7.04)
P value not reported
Favoured placebo
(attributed to more
antibiotics)
Statistically signifi-
cant difference
Unclear
Mannitol vs. nothing
Sputum volume:
mean in 75 minutes
25 (2) n = 14,1 trial, man-
nitol 480 mg MD
21.9%, CI not re-
ported, P value < 0.
001
n = 11, 1 trial: man-
nitol 300 mg, MD
22.3%, CI not re-
ported, P value < 0.
0001
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
HTS vs. ITS spu-
tum weight: (end-
point not reported)
24 (1) HTS median 5.3 g
(IQR 2.97 to 9.33)
; ITS median 3.17 g
(IQR 1.45 to 6.25)
Difference
Unclear Unclear
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Table 8. Outcomes in Cochrane reviews - sputum characteristics (Continued)
described as signifi-
cant but P value not
reported
Mucolytics vs.
placebo
(Wilkinson 2014)
Bromhexine vs.
placebo
Sputum volume: %
change at end of
trial
88 (1) MD -21.5% (-38.9
to -4.1), significance
not reported
P value not reported
Unclear Unclear
RhDNase 5 mg vs.
placebo
Sputum
colour (scale not ref-
erenced in trial) at
end of trial
40 (1) MD 0.28 (-0.04 to
0.60)
P value not reported
No evidence of ben-
efit for RhDNase 2.
5 mg
NSD No evidence of ben-
efit
Erdosteine vs. no
treatment
Mucous volume:
score
(0 = low, 1 = moder-
ate, 2 = high) at end
of trial
30 (1) MD 0.40 (-0.03 to
0.83),
P value not reported
NSD No evidence of ben-
efit
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Outcome not reported in trial
Nurse-led vs. doc-
tor-led care
(French 2003)
Not an outcome in the review
ACTs vs. no treat-
ment
(Lee 2013)
Sputum volume:
mL (end of session)
28 (2) n = 8, 1 trial, MD 8.
40 mL (3.40 to 13.
4), favoured ACT, P
value not reported
n = 20, 1 trial,
MD 24-hour vol-
ume, MD 3 mL,
P value = 0.02,
favoured ACT
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Sputum weight: g
(endpoint not re-
18 (2) n = 8, 1 trial, MD
17 g, P value < 0.01,
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
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Table 8. Outcomes in Cochrane reviews - sputum characteristics (Continued)
ported) favoured ACT
n = 10, 1 trial, MD
24 g, P value < 0.05,
favoured gravity-as-
sisted drainage; MD
0.01 g, P value > 0.
05, favoured control
1. People with bronchiectasis may expectorate 4-145 mL sputum in a 24-hour period (Tsang 2000), with mean daily volumes (based
on 4 studies) ranging from 65 to 567 mL(Pasteur 2010). We have not identified an MCID for sputum volume for bronchiectasis,
cystic fibrosis or chronic obstructive pulmonary disease.
For the purpose of this review, we regard increased expectoration of sputum as a positive outcome.
Abbreviations: ACT: airway clearance technique; CI: confidence interval; HTS: hypertonic saline; ICS: inhaled corticosteroid; IMT:
inspiratory muscle training; IQR: interquartile range; ITS: isotonic saline; LABA: long-acting beta2-agonist; MCID: minimal clinically
important difference;MD: mean difference; NSD: no significant difference; RhDNase: recombinant human deoxyribonuclease I; TDI:
Transitional Dyspnoea Index; vs: versus.
Table 9. Outcomes in Cochrane reviews - adverse events
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result
Evaluation
Pharmacological interventions
Antibiotics (long
term) vs. placebo
(Evans 2007)
Withdrawals due to
treatment failure or
adverse effects
260 (5) Peto OR 1.06 (0.42
to 2.65)
NSD No evidence of
harm
Diarrhoea 148 (2) Peto OR 2.47 (0.91
to 6.71)
NSD No evidence of
harm
Rash 54 (2) Peto OR 1.94 (0.19
to 19.47)
NSD No evidence of
harm
Wheeze 74 (1) Peto OR 8.56 (1.63
to 44.93)
More cases with an-
tibiotics
Statistically signifi-
cant difference
Evidence of harm
Dyspnoea 74 (1) Peto OR 4.41 (1.
43 to 13.61) Nebu-
lised antibiotics: 12/
37 vs. placebo: 3/37,
P value = 0.01
More cases with an-
tibiotics
Statistically signifi-
cant difference
Evidence of harm
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Table 9. Outcomes in Cochrane reviews - adverse events (Continued)
Chest pain 74 (1) Peto OR 8.84 (1.
88 to 41.50) Nebu-
lised antibiotics: 7/
37 vs. placebo: 0/37,
P value = 0.01
More cases with an-
tibiotics
Statistically signifi-
cant difference
Evidence of harm
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
AEs 74 (1, adults) OR 2.24 (0.86 to 5.
82)
31/37 (84%) peo-
ple in each group re-
ported at least 1 ad-
verse event
NSD No evidence of
harm
Inhaled corticos-
teroids vs. placebo/
no treatment
(Kapur 2009)
Outcome not reported in trial
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
AEs: frequency 40 (1) More adverse events
reported in the ICS
group (37) than the
LABA/ICS group
(12), but unclear
whether number of
events or number of
people experiencing
≥ 1 events reported
Unclear Unclear
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs. placebo
AEs
823 (2) OR 0.96 (0.61 to
1.51). The number
of AEs was high
in 1 study (placebo:
80% vs. mannitol:
82%), but most AEs
unrelated to treat-
ment
NSD No evidence of
harm
Mannitol vs. placebo
SAEs
823 (2) OR 0.79 (0.52 to 1.
19)
NSD No evidence of
harm
Mannitol vs. placebo:
AEs
50 (1) 2 peo-
ple receivingmanni-
tol haddrymouth; 4
reported headache,
fatigue, and chest
pain, but unclear if
AEs experienced in
NSD No evidence of
harm
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Table 9. Outcomes in Cochrane reviews - adverse events (Continued)
the same person. No
AEs reported in the
placebo group
HTS vs. ITS
Adverse events
59 (2) OR 8.20 (0.40 to
169.9)
NSD No evidence of
harm
Mucolytics vs.
placebo
(Wilkinson 2014)
Bromhexine vs.
placebo
AEs
88
(1)
OR 2.93 (0.12 to
73.97)
1 event (bromhex-
ine)
NSD No evidence of
harm
RhDNase 5 mg vs.
placebo
AEs
40 (1) Total of 19 AEs, not
differ-
ent between groups
but more cases of
influenza syndrome
in RhDNase (values
not reported)
No difference in AE
frequency for RhD-
Nase 2.5 mg
Unclear Unclear
RhDNase (2.5 mg)
vs. placebo
Antibody levels: fre-
quency
176 (1) OR 28.19 (3.77 to
210.85)
Statistically signifi-
cant difference
Evidence of harm
Erdosteine vs. no treatment: outcome not reported in trial
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Outcome not reported in trial
Nurse-led vs. doc-
tor-led care
(French 2003)
Not an outcome in the review
ACTs no treatment
(Lee 2013)
AEs 28 (2) None reported NSD No evidence of
harm
Withdrawals: inter-
vention-related
38 (3) No ACT-related
withdrawals
NSD No evidence of
harm
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Abbreviations: ACT: airway clearance technique; AE: adverse events; CI: confidence interval; HTS: hypertonic saline; ICS: inhaled
corticosteroid; IMT: inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; NSD: no significant differ-
ence; OR: odds ratio; RhDNase: recombinant human deoxyribonuclease I; SAE: serious adverse event; vs: versus.
Table 10. Outcomes in Cochrane reviews - hospitalisations
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result
Evaluation
Pharmacological interventions
Antibiotics (long-
term) vs. placebo
(Evans 2007)
Meannumber of ad-
missions per partici-
pant
17 (1, adults) MD -1.9, CI not re-
ported, P value = 0.
023
Fewer admissions
with antibiotics
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Number of admis-
sions
30 (1, adults) MD -0.6, CI not re-
ported, P value = 0.
038
Fewer admissions
with antibiotics
Statistically signifi-
cant difference
Evidence of statisti-
cal benefit
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
Not an outcome in the review
ICS vs. placebo/no
treatment
(Kapur 2009)
Outcome not reported in trial
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
Number of admis-
sions
40 (1) 4 events (1 LABA/
ICS vs. 3 ICS), OR
0.26 (0.02 to 2.79)
NSD No evidence benefit
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs. placebo:
Participants experi-
encing 1 or more
hospitalisations
461 (1) RR 0.61 (0.34 to 1.
09)
NSD No evidence benefit
Mannitol vs. nothing:
Outcome not reported in trial
HTS vs. ITS
Number
ofadmissions
40 (1) HTS 1 vs. ITS 3, P
value = 0.34
Only 4 events over-
all
NSD Unclear
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Table 10. Outcomes in Cochrane reviews - hospitalisations (Continued)
Mucolytics vs
placebo
(Wilkinson 2014)
Bromhexine vs. placebo:
Outcome not reported in trial
RhDNase 5 mg vs.
placebo
40 (1) OR 5.54 (0.25 to
123.08)
0 events in placebo
group
NSD No evidence of ben-
efit
Erdosteine vs. no treatment:
Outcome not reported in trial
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Outcome not reported in trial
Nurse-led vs. doc-
tor-led care
(French 2003)
Number of admis-
sions
80 (1) RR 1.59 (0.75 to 3.
39). Doctor-
led = 42 admissions,
nurse-led = 66 ad-
missions.More than
1 admission per per-
son
NSD No evidence of ben-
efit
ACTs vs. no treat-
ment
(Lee 2013)
Outcome not reported in trial
Abbreviations: ACT: airway clearance technique; CI: confidence interval; HTS: hypertonic saline; ICS: inhaled corticosteroids; IMT:
inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; MD: mean difference; NSD: no significant
difference; OR: odds ratio; RhDNase: recombinant human deoxyribonuclease I; RR: risk ratio; vs: versus.
Table 11. Outcomes in Cochrane reviews - mortality
Intervention/
comparison
Outcome Number of partic-
ipants (number of
studies)
Results: treatment
effect (95%
CI) unless other-
wise stated
Interpretation of
result
Evaluation
Pharmacological interventions
51Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 11. Outcomes in Cochrane reviews - mortality (Continued)
An-
tibiotics (long term)
vs. placebo (Evans
2007)
Deaths 128 (2, adults) Peto OR 0.57 (0.07
to 4.54)
4 deaths
NSD No evidence of
harm
Antibiotics (short
term) vs. placebo
(Wurzel 2011)
Not an outcome in the review
ICS vs. placebo/no
treatment
(Kapur 2009)
Outcome not reported in trial
LABA/ICS combi-
nation vs. ICS
(Goyal 2014)
Deaths 40 (1) 0 deaths - -
Inhaled hyperosmo-
lar vs. placebo or
ITS
(Hart 2014)
Mannitol vs. placebo:
Deaths
363 (1) 2 deaths in the
mannitol group that
were not treatment
related
Unclear Unclear
Mannitol vs. noth-
ing:
Deaths
25 (2) 0 deaths - -
HTS vs. ITS:
Deaths
113 (4) 0 deaths - -
Mucolytics vs.
placebo
(Wilkinson 2014)
Outcome not reported in trials
Non-pharmacological interventions
Physical ther-
apy: IMT vs. no in-
tervention or sham
treatment
(Bradley 2002)
Not an outcome in the review
Nurse-led vs. doc-
tor-led care
(French 2003)
Outcome not reported in trial
ACTs vs. no treat-
ment
(Lee 2013)
Outcome not reported in trial
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Abbreviations: ACT: airway clearance technique; CI: confidence interval; HTS: hypertonic saline; ICS: inhaled corticosteroids; IMT:
inspiratory muscle training; ITS: isotonic saline; LABA: long-acting beta2-agonist; NSD: no significant difference; OR: odds ratio;
vs: versus.
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